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I. Abstract 
I.1. Abstract (English) 
 
Introduction: Alcohol use disorder (AUD) is a chronically relapsing disorder and 
characterized by dysfunctional learning or in other words the continued intake of alcohol despite 
negative consequences. Cognitive processes of decision-making, information-updating and set-
shifting are associated with the prefrontal cortex (PFC) that is involved in these so called 
executive functions (EF). The dopaminergic (DA) neurotransmitter system plays a significant 
role in the modulation of reward learning and can be disrupted in AUD. D2/3 receptor (D2/3R) 
availability in the striatum has been positively associated with performance on laboratory tests 
that reflect and rely on EF. Also, striatal D2/3R availability is typically lower in detoxified AUD 
patients than in healthy controls. It has been shown that chronic alcohol consumption can have 
an effect on extrastriatal D2/3R availability. This is especially of interest in areas connected to 
prefrontal integrity and EF. However, only a few studies have examined extrastriatal D2/3R 
availability in AUD and its relation to performance in laboratory measures of EF. We aim to 
determine this relationship with a focus on group differences between low risk controls (LR), 
high risk subjects (HR) with a score > 8 in the Alcohol Use Disorder Identification Test 
(AUDIT) and AUD patients. 
Methods: We included 58 subjects (19 LR, 19 HR and 20 AUD) who were equally 
assessed in EF performance. Extrastriatal D2/3R availability was examined with (18F)-Fallypride 
(FAL) positron emission tomography/computed tomography (PET/CT) and magnetic resonance 
imaging (MRI) and brought in relation to performance on common laboratory measures of EF.  
Results: Differences in extrastriatal non-displaceable binding potential (BPND) for FAL 
were observed in several regions of interest (ROIs) (bilateral dorsal anterior cingulate cortex 
(ACC), bilateral rostral ACC, left dorsolateral prefrontal cortex (PFC) and left ventrolateral 
PFC). Patients presented significantly less BPND in a number of these areas when compared to 
HR. EF tests amongst the groups differed in a Digit Span Backwards task. AUD showed a 
significantly better performance when compared to LR. Performance in the Trail-Making Test 
Part B (TMT-B) showed a trend to be decreased amongst LR compared to HR and AUD. 
Extrastriatal BPND in several ROIs was negatively correlated with TMT-B performance.  
Conclusion: Alcohol consumption has an impact on extrastriatal D2/3R availability and 
can influence DA transmission in subregions of the ACC and the PFC. This study is adding 
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evidence to a growing body of work with heterogeneous results of responses to chronic alcohol 
consumption and its impact on EF performance. 
 
I.2. Abstract (German) 
 
 Hintergrund/Einleitung: Alkoholabhängigkeit (AUD) ist eine chronische Erkrankung, die 
im Krankheitsverlauf durch Rückfälle gekennzeichnet ist. Dies wird zum Teil auf 
dysfunktionales Lernverhalten zurückgeführt, da der Konsum trotz negativer Konsequenzen 
weitergeführt wird und keine Verhaltensanpassung erfolgt. Dafür wichtige Prozesse wie 
Entscheidungsfindung, mentale Flexibilität und Anpassungsfähigkeit werden mit dem 
präfrontalen Kortex (PFC) assoziiert und unter dem Begriff Exekutiv Funktionen (EF) 
zusammengefasst. Diese können bei AUD geschwächt sein. Der Neurotransmitter Dopamin 
(DA) spielt eine Rolle bei der Modulation von Lernvorgängen im Gehirn, vor allem im 
Belohnungslernen. Das DA-System kann bei chronischem Alkohol Konsum stark verändert sein. 
So korreliert beispielsweise eine höhere D2/3-Rezeptorverfügbarkeit (D2/3R) im Striatum mit 
besserem Abschneiden in Tests, die EF testen. Die D2/3-Rezeptorverfügbarkeit im Striatum ist 
bei AUD typischerweise erniedrigt. Es lässt sich also vermuten, dass auch extrastriatale DA-
vermittelte Veränderungen bei chronischem Alkoholkonsum eine Rolle spielen. Diese 
Veränderungen können in Bereichen wie dem PFC auftreten, die für EF wichtig sind. Jedoch 
haben nur wenige Studien die extrastriatale D2/3-Rezeptorverfügbarkeit in AUD untersucht. 
Auch die Verbindung zum Abschneiden in EF Tests ist bisher nicht eingehend untersucht 
worden. In dieser Studie wollen wir eine Assoziation von D2/3-Rezeptorverfügbarkeit und dem 
Abschneiden in EF Tests überprüfen. Dies geschieht mit einem Fokus auf die Unterscheidung in 
Kontrollen (LR), Hochrisiko-Konsumenten (HR) mit einem Score > 8 im Alcohol Use Disorder 
Identification Test (AUDIT) und alkoholabhängige Patienten (AUD). 
 Methoden: Es wurden 58 Subjekte eingeschlossen (19 LR, 19 HR, 20 AUD). Alle 
Teilnehmenden durchliefen eine Abfolge von neuropsychologischen Tests. Die extrastriatale 
D2/3-Rezeptorverfügbarkeit wurde mittels (18F)-Fallypride (FAL) Positronen-Emissions-
Tomographie/Computertomographie (PET/CT) und Magnetresonanztomographie (MRI) 
gemessen und mit den experimentellen Messergebnissen in Verbindung gesetzt.  
Ergebnisse: Das extrastriatale non-displaceable binding potential (BPND) unterscheidet 
sich im Gruppenvergleich in mehreren ROIs (bilateraler dorsaler anteriorer zingulärer Kortex 
(ACC) und rostraler ACC; linker dorsolateraler PFC und linker ventrolateraler PFC). Bei 
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Patienten zeigte sich ein signifikant geringeres BPND im Vergleich zu HR. In den EF Tests wurde 
ein Unterschied im Abschneiden im Digit Span Backwards Test gefunden, wobei Patienten 
signifikant besser abschnitten als LR. Auch beim Trail-Making Test Part B (TMT-B) konnte ein 
entsprechender Trend beobachtet werden. Das BPND war in mehreren Regionen negativ mit dem 
Abschneiden im TMT-B korreliert.  
 Schlussfolgerung: Alkoholkonsum kann einen Einfluss auf die extrastriatale 
Verfügbarkeit von DA Rezeptoren haben und dopaminerge Signalübermittlung vor allem in den 
Unterregionen des ACC sowie des PFC beeinflussen. Diese Arbeit fügt weitere Erkenntnisse zu 
den heterogenen Ergebnissen in diesem Feld hinzu, auch bezüglich der Beziehung zu EF. 
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II. Introduction 
 
For the remainder of this work ethanol will be referred to as alcohol, and alcoholism and 
alcohol addiction/dependence are the functional equivalent of alcohol use disorder as described 
in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM V). Executive 
functions and executive functioning will also be used as synonyms. All tables and figures were 
produced by the author of the present work. References to the original, if based on such, are 
named in the description of the table/figure. 
 
II.1. Alcohol Use Disorder 
II.1.1. Definition, Dimensional and Categorical Approach  
 
Ethanol, a widely consumed and abused substance, causes multiple alcohol-related 
problems (ARP) in social, mental and physical health (Lange, Manz, Rommel, Schienkiewitz, & 
Mensink, 2016; World Health Organisation, 2014). Worldwide, problematic alcohol 
consumption ranks amongst the top five risk factors for the development of diseases, disabilities 
and deaths for both sexes (Lim et al., 2012; World Health Organisation, 2014).  
Alcohol use disorder (AUD) is the most common of all substance use disorders (SUD) 
and represents the most pronounced and severe form of alcohol misuse. It is a chronically 
relapsing disorder characterized by the compulsion to seek and take the drug, the loss of control 
in limiting the intake, the emergence of negative emotional states as well as dysfunctional 
learning – or in other words, by the continued intake of alcohol despite negative consequences. 
Since 2013, the Diagnostic and Statistical Manual of Mental Disorders (DSM V) includes not 
only a categorical but also a dimensional approach within the AUD diagnosis – encompassing 
not only the dependence on, but also the abuse, of alcohol. AUD can thus be defined as a mild 
(meeting 2 or 3 criteria), moderate (meeting 4-5 symptoms) or severe disorder (meeting six or 
more criteria) at the time of diagnosis (American Psychiatric Association, 2013). This approach 
and change does not distinguish between the clear term dependence and the less defined term 
abuse and implies that these two belong to the same disease entity (Batra et al., 2016; Heinz & 
Friedel, 2014). If seen on a continuum, they could be preceded by abstinence, low-risk (LR) 
consumption and high-risk (HR) consumption. The DSM V lists a total of 11 criteria that cover 
four characteristic symptom classes (see table 1). 
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As discussed in Helzer et al. (2006), there is evidence that all SUDs could be arrayed 
along a continuum concerning their intensity. This is of high interest not only in theory but also 
important in the monitoring and prevention of disorder progression and concerning treatment 
efforts that can thus address the full range of a disorder. A variety of tools and questionnaires 
such as the alcohol use disorder identification test (AUDIT), alcohol and drug questionnaire 
(ADQ) and CAGE (acronym for four screening questions concerning the “cut down” of 
consumption/ “annoyed” about consumption/ “guilt” feelings/ “eye opener” in the morning) are 
in regular use for identification and quantification of AUD. Not only is there a dimensional 
approach to the disorder itself but likewise in alcohol consumption patterns concerning 
frequency, quantity and motivation. Therefore, not only the disorder as such but also the specific 
patterns of no alcohol intake, LR, HR consumption and the different levels of AUD can be 
arrayed along the continuum. Identifying subjects with a HR consumption pattern and preventing 
progression to disorder diagnosis is the main goal of the tools mentioned above.  
 
On the other hand, a categorical approach that helps to define if a subject is suffering or 
not suffering from a disease or disorder is necessary, not only for social acceptance but 
especially for decision-making in clinical contexts. This is illustrated by the following statement: 
“Clinicians who must decide whether to treat or not treat a patient, to hospitalize or not, to treat a 
patient with drug or with psychotherapy, to use this drug or that drug, [...] must inevitably use a 
Meeting 2-3 criteria = mild; 4-5 criteria = moderate; ≥ 6 criteria = severe disorder.  
Retrieved from the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition; American Psychiatric Association (2013) 
Table 1. DSM V Criteria for Alcohol Use Disorder Diagnosis  
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categorical approach to diagnosis” (Kraemer, Noda, & O’Hara, 2004). Therefore, it is essential 
to link dimensional and categorical approach with one another.  
 
II.1.1.2. High-risk Drinking Patterns 
 
Treatment-seeking patients with AUD diagnosis represent only a small fraction of people 
who abuse alcohol, but many more individuals consume alcohol to a harmful extent without 
fulfilling enough criteria to be classified as AUD patients (World Health Organisation, 2014). In 
Germany, approximately 13.1 % of the female and 18.5% of the male population aged 18 to 79 
years consume a potentially harmful daily amount of alcohol (Lange et al., 2016). They have 
been described as HR consumers and are often unaware of their problematic alcohol intake and 
its possible consequences. Various definitions have been established to describe cut-offs and 
subclasses of HR consumption. For instance, the intake of more than 10 g of pure ethanol per 
day for women and more than 20 g per day for men (Lange et al., 2016) or the risk (hazardous 
use) or presence (harmful use) of physical or psychological harm (World Health Organisation, 
2016). The Deutsche Hauptstelle für Suchtfragen classifies the following subgroups of daily 
alcohol consumption (in the last 30 days) as shown in table 2. 
 
However, not only the quantity of alcohol consumption plays a role in the definition of 
HR drinking. Also drinking patterns and physical, psychological and social consequences and 
components need to be included. As mentioned before, a well-known and widely used tool for 
their identification is the AUDIT (for more detailed information see III.2.1). This questionnaire 
goes further than the sole definition by quantity and addresses different distinctions of 
problematic alcohol intake with regard to categorical and dimensional approaches. The questions 
are aimed at the following subgroups shown in table 3. 
Table 2. Classification of daily Alcohol Consumption according to Deutsche Hauptstelle für Suchtfragen. 
  
Retrieved from Seitz, Lesch, Spanagel, Beutel, & Redecker (2013). 
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 People involved in binge drinking or heavy episodic drinking (HED) are part of a special 
subgroup and present a more clearly defined drinking pattern that is classified as being a high-
risk behaviour of alcohol consumption. It is defined as the intake of 60 g or more of pure ethanol 
(an equivalent of 5 or more standard drinks) on a single occasion at least once a month (World 
Health Organisation, 2014). However, obviously it needs to be seen in relation to different 
aspects such as blood alcohol concentration (BAC), gender, age, BMI and other individual 
factors. In this context, the hazardous and harmful as well as problematic use are summarized 
under the term of HR consumption. This comprises not only the potential harm to the consuming 
subject but also the possible effects on other individuals, such as children, partner, co-workers or 
strangers in contact with the subject. 
 
II.1.2. Epidemiology  
 
AUD is a common psychiatric disorder with devastating consequences (medical, social, 
financial) for affected individuals and their relatives. In 2012, 3.4 % of the German adult 
population (4.8 % of the male and 2.0 % of the female population, about 1.8 million people) met 
the DSM IV or ICD 10 criteria for an AUD diagnosis (Pabst, Kraus, Matos & Piontek, 2013). An 
additional 3.1 % (4.7 % of men and 1.5 % of women) met the criteria for harmful alcohol abuse 
(Pabst et al., 2013). The prevalence of problematic alcohol consumption as identified by the 
AUDIT (including HED) is very common. The estimated prevalence in Germany varies between 
21.1 % (amongst men: 32.4 % and women: 8.9 %) according to Kraus, Pabst, Piontek, & Müller 
(2010) and 41.5% for men and 25.6% for women (Hapke, v. der Lippe, & Gaertner, 2013). 
German hospitals listed alcohol-related disorders as the main diagnose in the year 2016 with 322 
608 treatment cases (Statistisches Bundesamt, 2017). 5.1 % of the global burden of disease and 
Table 3. Aspects of High Risk Drinking Behaviour as assessed with the AUDIT Questionnaire 
Retrieved from Barbor, Higgins-Biddle, Saunders, & Monteiro (2001) 
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injury is attributable to alcohol, as measured in disability-adjusted life years (DALYs) and about 
3.3 million deaths (5.9 % of all global deaths) were attributable to alcohol consumption in the 
year 2012 (World Health Organisation, 2015). Furthermore, individuals with AUD have a large 
number of psychiatric co-morbidities such as depression and suicidal behaviour, bipolar 
disorders, anxiety disorders, insomnia or other SUD. There is also a causal relationship to the 
development of many somatic diseases, injuries and deaths (World Health Organisation, 2015). 
HR alcohol consumption and AUD are partly responsible for more than 200 conditions such as 
non-communicable diseases like cancers (especially in the gastro-intestinal tract), liver 
dysfunction, coronary heart disease, neurological diseases, fetal alcohol spectrum disorders 
(FASD) and infectious diseases (Lange et al., 2016; World Health Organisation, 2015).  
Alcohol consumption and AUD are also causing high direct and indirect costs to society. 
In Germany the total costs added up to 24.398 billion euros in the year 2002 – taking into 
account treatments of AUD and somatic diseases associated with alcohol consumption, loss of 
working hours and mortality (Küfner, 2010).  
Relapse rates amongst AUD patients lie at about 85 % when no further treatment 
(psychotherapeutic and pharmacological) after the initial detoxification is arranged (Boothby & 
Doering, 2005; Walter et al., 2015), emphasizing the chronic condition of the disorder and the 
life-long struggle for the patients.  
 
II.1.3. Aetiology 
 
AUD is a complex disease; the aetiology and development are unclear in their details. 
Most likely, different components interact in form of a bio-psycho-social model (BPS). Amongst 
others, factors such as alcohol-related neurological changes, individual dispositions (e.g. 
genetic/biological, psychological) as well as environmental and cultural aspects seem to have an 
effect on problematic alcohol-related behaviour and, its most pronounced form, AUD. There is 
little doubt that learning mechanisms, especially in reinforcement learning, play a central role in 
AUD development. Repeated alcohol consumption despite negative consequences or absence of 
positive consequences may be due to an impaired flexibility in changing and adapting to 
environmental changes (e.g. reward contingencies (Park et al., 2010)). This learning deficit is of 
great clinical relevance during disorder development, therapy as well as for the psychosocial 
outcome (von der Goltz & Kiefer, 2009). Qualities, unique to mankind, that verify and adapt 
behaviour in relation to changing environmental circumstances and outcomes fall under so called 
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executive functioning (EF) (for more detailed information see II.3.) that may be impaired in 
AUD patients (Ratti, Bo, Giardini, & Soragna, 2002). It is hard to distinguish if this is a 
condition prior to the consumption or a consequence of repeated alcohol intake.  
 
[...] to understand the effects of alcoholism, it is important to consider the influence of a 
wide range of variables on a particular behaviour or set of behaviours. The underpinnings of 
alcohol-induced brain defects are multivariate; to date, the available literature does not support 
the assertion that any one variable can consistently and completely account for these 
impairments. Instead, the identification of the most salient variables is a primary focus of 
current research. In the search for answers, we recommend an integrative approach that 
recognizes the interconnectivity of the different functional systems to account for the 
heterogeneity of outcome variables associated with alcoholism-related impairments and 
recovery of functions. (Oscar-Berman et al., 2014) 
 
 
II.1.3.1. Diathesis-Stress Model and Risk Factors 
 
With today’s understanding of the development of psychiatric disorders or diseases, the 
most suited approach towards AUD (and other psychopathologies) may be the diathesis-stress 
model, a psychological theory trying to explain behaviour as an outcome of individual 
vulnerability (diathesis) and external factors (stress, negative events) (Hankin & Abela, 2005). It 
serves to explore how individual predispositions (e.g. genetic and biological traits, family 
history, early life experiences, cognitive factors, personality traits) interact with stressors from 
the environment (e.g. socio-cultural environment, long-term negative conditions, discrete 
stressful life events) to enhance the development of disorders. Using this approach, it is also 
possible to describe risk and protective factors, moderators and mediators that work on a 
dynamic and reciprocal basis. It is even possible to make predictions about individuals who are 
at a higher risk of developing a disorder than others (Gazelle & Ladd, 2003; Hankin & Abela, 
2005).  
A large number of twin and adoption studies have been performed in recent decades and 
were able to show a strong heritability of AUD, estimated at around 50 % (Kendler, 1997). For 
example, a subject can be highly vulnerable to a certain disorder (e.g. for AUD because of a 
positive family history of AUD) but does not develop the disorder until exposed to certain 
stressors. Another individual might not develop the disorder despite being exposed to the same 
stressors. This can indicate less vulnerability (e.g. no family history) to a particular disorder, 
differing susceptibility, more risk-resilience or protective factors amongst the individuals. These 
resilience factors can also be both genetic and environmental. For example, functional 
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polymorphisms in the alcohol dehydrogenases (ADH) and aldehyde dehydrogenases (ALDH) 
are common amongst Chinese and other East Asian individuals and increase their sensitivity to 
alcohol. Consumption of alcohol leads to adverse effects such as flush symptoms, nausea and 
vomiting that prevent individuals from the intake (Thomasson et al., 1991). Protective 
environmental factors can include for example less alcohol availability, intact family structures 
with support from family members and friends, better coping strategies, more resources or less 
exposure to stress (Enoch, 2006). With growing scientific evidence about the multifactorial 
origins and favourable conditions of AUD development, a number of important risk factors can 
be identified (see figure 1). 
 
 Individual risk and predisposition may be due to negative early life experiences and 
include factors such as the socioeconomic status, personality traits (e.g. impulsivity), 
psychopathology and comorbidities (e.g. depression, anxiety or bipolar disorder). Other possible 
risk factors are differences in cognitive and EF abilities, male gender and other biological factors 
(e.g. genetic vulnerability, positive family history) as well as the alteration of neurological 
circuits due to alcohol consumption itself. Environmental factors play an important role on 
different levels (macro, micro and community) and contain aspects such as social acceptance and 
availability of alcohol, cultural drinking practice, peer group pressure and influence, parental 
lifestyle or dysfunctional family structures and exposure to stress or traumatic life events.  
Figure 1. Social, cultural and individual Risk Factors of AUD Development  
 Adapted from Sudhinaraset et al. (2016) 
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II.1.3.2. Learning and Alcohol Use Disorder 
 
Many psychological disorders also have a certain time span of vulnerability, during 
which a subject is more likely to develop a disorder if exposed to negative stressors. Concerning 
the development of AUD, adolescence and young adulthood are critical timespans with high 
vulnerability, as the central nervous system (CNS) is widely trying out, establishing and 
maintaining mechanisms and behaviours. Also, the prefrontal dopaminergic system undergoes 
important modifications, mainly starting in adolescence and continuing in early adulthood 
(Yetnikoff, Reichard, Schwartz, Parsely, & Zahm, 2014). This may make this important 
neurotransmitter system especially vulnerable during this time. Many AUD patients report to 
have started drinking earlier than matched healthy controls and around 40% of alcoholics were 
already drinking heavily at the end of their adolescence (Enoch, 2006). When, if and how 
individuals start drinking is strongly influenced by environmental, individual and genetic factors 
mentioned above (Hägele, Friedel, Kienast, & Kiefer, 2014; Sudhinaraset, Wigglesworth, & 
Takeuchi, 2016). 
It is common for individuals to have their first contacts and make positively rated social 
experiences with alcohol during adolescence. In terms of classical conditioning, this can lead to a 
positive connotation of the substance in the sense of a conditioned stimulus (CS). The activation 
of reward structures in the brain (positive reinforcement) related to the CS plays a central role. 
Later in AUD development, it is mainly the alleviation of unpleasant conditions such as craving 
and withdrawal (negative reinforcement) that enhances the addictive behaviour. Addictive 
behaviour can thus be seen as a learned behaviour. 
On the neurobiological level, persistent alterations of behaviour and psychological 
functioning are thought to be mediated by reorganization, modification and strengthening of 
synaptic connections in specific neural circuits and occur as a consequence of experience and 
learning. Changes on structural, neuronal and molecular level (e.g. neurotransmitter imbalances, 
neuro-adaptive responses) caused by chronic application of addictive drugs, have been shown in 
preclinical studies (Nestler, 1997; Terry E. Robinson & Kolb, 2004). They show similarities to 
physiological mechanisms of learning, such as in long term potentiation (LTP) (von der Goltz & 
Kiefer, 2009). These changes and adaptations of brain circuits can persist long beyond 
detoxification especially in cases of severe disorders with an impact on leaning capacity, 
neuropsychological functioning and EF (Stavro et al., 2013). This is of high clinical relevance. 
During inpatient treatment and during further rehabilitation, most strategies ask patients to learn 
new information and mechanisms to change and control their behaviour, to interact with others 
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and make difficult causal connections between situations, feelings and actions – all that in order 
to avoid the learned pattern that alcohol-related cues are followed by consumption. In this case, 
as shown in several studies, higher levels of neuropsychological functioning are associated with 
higher rates of successful inpatient treatment (O’Leary, Donovan, Chaney & Walker, 1979). 
Also, the attendance of outpatient groups (Guthrie & Elliott, 1980) and employment success 
correlate positively with intact neuropsychological functioning (McCrady & Smith, 1986; Meek, 
Clark & Solana, 1989). AUD is to a certain extent connected to dysfunctional learning 
mechanisms (Garbusow et al., 2016; Sebold et al., 2014). For an extensive review of learning 
mechanisms and risk factors for AUD development see Hägele et al. (2014) as a more detailed 
inquiry would exceed the framework of this exploration. More detailed information on explicit 
pathways, reward learning and molecular effects can be found in section II.2. 
 
II.2. Neurobiology of Alcohol Use Disorder 
 
Ethanol does not have a specific binding site in the brain but is thought to interact with a 
number of ethanol receptive elements in cell membranes, such as ligand-gated ion channels. 
Acute intoxications with ethanol cause direct cellular damage that lasts for hours, whereas 
chronic intake leads to widespread neuroadaptive processes in the CNS such as remodelling of 
synapses, altered neuro-transmission and neuro-adaptation. These changes can last for much 
longer, up to a lifetime. The effect on the CNS includes specific changes in cell function, gene 
expression, epigenetic modification and affects multiple neurotransmitter systems (GABAergic, 
glutamatergic, serotoninergic, opioid and dopaminergic) and brain circuits (Heinz et al., 2009; 
Most, Ferguson, & Harris, 2014). These effects are also reflected by their opposing reaction 
during withdrawal. The sum of molecular and cellular changes ultimately results in altered 
behavioural responses. The exact mechanisms and their interaction are, however, very complex 
and not yet completely understood. The following section will give a brief overview of the most 
important transmitter systems and their involvement in the development and maintenance of 
AUD. 
 
γ-aminobutyric acid 
 γ-aminobutyric acid (GABA) is the main inhibiting transmitter in the mammalian CNS. 
Thus, its main role is to control and diminish neuronal excitability via negative changes of the 
membrane potential via inflow of negative ions or out-flow of positive ions. GABA mainly binds 
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to two different types of receptors, an inhibitory ligand-gated ion-channel (GABAA) and a 
metabotropic, G-protein-coupled receptor (GABAB). Ethanol and other substrates such as 
benzodiazepines, barbiturates, anaesthetics and anticonvulsants act on allosteric binding sites as 
agonists and multiply the activity of GABAA receptors (Sieghart, 1995). The receptors allow the 
flow of chloride (Cl-) across the membrane into the cell. This leads to hyperpolarisation, 
inhibitory postsynaptic potentials (IPSP), less excitability of the targeted neuron and thus 
weakens the stimulating signals of e.g. glutamate (Sieghart, 1995). The inhibitory effects include 
sedation, impaired cognitive functions, anxiolytic and anticonvulsive effects as well as muscle 
relaxation and motor inco-ordination. All these are enhanced by alcohol. Chronic alcohol intake 
can cause a down-regulation of GABAA receptors due to the excessive stimulation as shown in 
figure 2 (Most et al., 2014). During acute withdrawal from alcohol or other potentiating drugs, 
this results in a relative shortage of inhibiting GABA effects due to the missing reinforcement on 
GABAA receptors leading to dysbalance between stimulating and inhibiting transmission.  
 
Glutamate 
 Glutamate is the main excitatory transmitter in the CNS. Glutamatergic transmission uses 
both metabotropic (mGluR) and ionotropic (N-methyl-d-aspartate (NMDA) and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)) receptors. This particular system plays a 
key role in LTP and long-term depression (LTD), molecular correlates of learning and memory 
effects that are mediated mainly by repeated NDMA receptor stimulation. All receptors for 
glutamate are inhibited under the influence of alcohol, although some subtypes are affected only 
when very high concentrations of ethanol are present. Acute actions of alcohol on the 
glutamatergic system are involved in tolerance, withdrawal, craving, relapse and dependence 
(Tsai, 1998). Ethanol works as a non-competitive antagonist on AMPA receptors but needs to 
show high concentrations to affect transmission, whereas NMDA receptors are very sensitive to 
ethanol’s acute antagonizing effects (Most et al., 2014). Chronic intake however seems to 
enhance NMDA receptor expression (Qiang & Ticku, 2005) leading to an upregulation to 
counteract the inhibition of the glutamatergic system and the inhibiting effects of increased 
GABAergic transmission under alcohol influence (for acute and chronic changes in synaptic 
transmission also see figure 2). Typical symptoms during withdrawal such as anxiety, dysphoria 
and, in severe cases, convulsions, are caused by the dysbalance between excess of glutamate 
receptors and a lack of GABAA receptors (Most et al., 2014). To prevent severe conditions such 
as seizures, a temporary treatment with anticonvulsive medication (e.g. benzodiazepines) is 
sometimes needed.  
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Serotonin  
 The neurotransmitter serotonin (5-HT) is involved in mood regulaton, sleep, appetite, 
learning, memory and others important functions. 5-HT neurons originate from the raphe nuclei 
and project almost into the entire brain. Most receptor subtypes are metabotropic and use 
secondary messenger pathways, except for the 5-HT3 receptor which is a ligand-gated ion 
channel. Alcohol enhances serotonergic transmission in part by increasing the potency of 5-HT3 
receptor activation (Sung, Engel, Allan, & Lovinger, 2000). Generally, an inverse relation 
between alcohol consumption and 5-HT transmission can be observed (Most et al., 2014). 
Studies showed a reduction in brainstem 5-HT transporters that were correlated with lifetime 
alcohol intake in male detoxified alcoholics (Heinz et al., 1998). Reduced 5-HT transporters 
have also been shown in major depressions and were also directly associated with high anxiety 
and depression, particularly during acute withdrawal (Heinz et al., 1998).  
 
Opioid 
 Berridge and Robinson (1998) suggested that the opioid system is responsible for the 
direct mediation of the hedonic effects of alcohol consumption. Studies with rodents have shown 
increased µ-opiate receptors in the ventral striatum amongst animals that prefer alcohol (Cowen 
& Lawrence, 1999). Increased µ-opiate receptors have also been found in AUD patients during 
early abstinence and even showed a correlation between high numbers of receptors in the ventral 
striatum and medial PFC (mPFC) and craving for alcohol (Heinz, Reimold et al., 2005a). The 
opioid system clearly interacts with reinforcing mechanisms of alcohol, as the opioid antagonist 
naltrexone has proven to be effective in decreasing alcohol consumption and craving (clinically 
and experimentally) and can also be used to prevent relapses in some individuals after 
detoxification treatment (Anton, 2008). Increased opioid activity caused by alcohol consumption 
also appears to facilitate dopamine (DA) release in the ventral tegmental area (VTA) and nucleus 
accumbens (NAc) (Anton, 2008) emphasizing the interconnectivity of neurotransmitter systems.  
 
Dopamine 
 In AUD, alterations in the dopaminergic system play a central role. Especially 
dysfunctions during early abstinence are thought to be partly responsible for the problems with 
unlearning of well-established responses to alcohol-associated cues and learning motivational 
responses to new stimuli (Heinz et al., 2009). The role of DA in learning, reward and different 
brain circuits will be discussed in detail in the section about the dopaminergic system below 
(section II.2.1.).  
 19 
II.2.1. The Dopaminergic System 
 
Dopamine (from 3,4-dihydroxyphenethylamine) is a catecholamine and an important 
neurotransmitter in the CNS. It also plays different other important roles in the human body, 
including influence on cardiac output, vasodilatation, renal blood flow and urine output. DA is 
synthesized as a precursor chemical (L-DOPA) in brain and kidneys. After decarboxylation, it 
can bind to different types of dopamine receptors. In the CNS, we have two main classes of 
receptors: D1- and D2-like receptors, all of them are G-protein-coupled receptors that transmit 
information via secondary messengers and molecular cascades. Depending on the type of 
receptor, DA can act as an inhibiting or stimulating transmitter on other neurons. When binding 
to D1-like receptors (D1/5R) DA provokes increased intracellular cAMP via Gs-proteins that can 
lead to inhibition (e.g. opening potassium (K+) channels, leading to hyperpolarisation) or 
excitation (e.g. opening sodium (Na+) channels leading to depolarisation) on the targeted neuron. 
The activation of D2-like receptors (D2/3/4R) generally leads to inhibition of the targeted neuron, 
and they also have a higher affinity to DA than D1-like receptors (Seamans & Yang, 2004). DA 
cannot be seen as a clearly inhibiting or excitatory neurotransmitter but rather as a 
neuromodulator on synaptic transmission that potentiates or attenuates responses (Seamans & 
Yang, 2004).  
Multiple diseases of the nervous system are connected to DA dysfunctions. For example, 
in Parkinson’s disease, a massive loss of DA neurons in the substantia nigra pars compacta 
(SNc) leads to typical motor symptoms such as shaking, rigidity, postural instability as well as 
psychiatric problems including depressions, dementia and emotional problems. Parkinson’s 
disease can be initially treated with the substitution of L-DOPA (Scatton, Javoy-Agid, Rouquier, 
Dubois, & Agid, 1983). There is also evidence that schizophrenia is related to altered levels of 
DA. Treatment options for the latter involve a reduction of DA transmission by using 
antipsychotic drugs that act as DA antagonists (Seeman, 1987).  
Cell bodies of DA neurons are concentrated mainly in the VTA and the SNc. The latter is 
a component of the basal ganglia and the nigrostriatal pathway that is crucial for motor function 
and is affected in Parkinson’s disease. DA neurons are also found in the hypothalamus, affecting 
the secretion of the hormone prolactin from the pituitary gland via the tubero-infundibular 
pathway. DA reaches the pituitary gland via the hypophyseal portal system and inhibits the 
secretion of prolactin which otherwise is secreted continuously. In this context, DA is also called 
prolactin-inhibiting factor (PIF). The dopaminergic neurons that lie in the VTA project via the 
medial forebrain bundle (MFB) into different parts of the brain, including limbic (amygdala, 
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NAc, septum, hippocampus) and cortical regions such as the PFC. This circuit is called 
mesocorticolimbic projection and is thought to be involved in reinforcement, reward learning 
and motivation (see below).    
Figure 2. Synaptic Transmission and Neuroadaptations after (A) acute and (B) chronic Alcohol 
Exposure                                                                                 Retrieved and adapted from Most et al. (2014) 
 
PFC = Prefrontal cortex; NMDA-R = N-methyl-d-aspartate receptor; DA = dopamine; DA-R = DA receptor; NAc = 
nucleus accumbens; Amg = amygdala; VTA = ventral tegmental area; GABA = γ-aminobutyric acid; GABA-R = 
GABA receptor 
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II.2.1.1. Dopamine and Reward – Mesocortical and Mesolimbic Circuits 
 
As stated above, DA plays a role in different pathways in the brain. We will now focus 
on the mesocortical and mesolimbic pathways that are thought to be involved in the development 
of drug addiction and to play a major role in reward-motivated behaviour.  
Acute alcohol exposure activates dopaminergic reward pathways, whereas chronic intake 
leads to hypodopaminergic states (see figure 2) that are associated with dysphoria and may lead 
to craving and relapse (Koob & Volkow, 2010). Changes in the motivation for drugs and natural 
rewards play a key role in addiction. As Robinson & Berridge (1993) suggested, DA mediates 
mainly a motivational response and is associated with the craving or wanting of drugs of abuse 
and does not directly mediate the hedonic effect of alcohol. It is nevertheless highly linked to 
reward learning processes. Rewards as such are needed for individual and gene survival and 
enhance behaviour and elementary processes such as drinking, eating and reproduction. As 
described by Mirenowicz & Schultz (1994), firing patterns of DA neurons can be either in a 
tonic mode with a low frequency or in a phasic mode with a higher frequency. The latter leads to 
a transient increased DA release, which is thought to signal the salience of a cue. Phasic bursts 
occur especially in early stages of reward learning when a reward is presented. Over time, a 
stimulus-action-reward mechanism is encoded. If the predicted reward fails to appear, activity is 
inhibited and if the reward appears sooner than thought, DA responses increase again. Thus, DA 
neurons in the midbrain seem to be coding the so called prediction error (PE), the degree to 
which a reward, or a certain cue that is associated with reward, is new and surprising (Schultz, 
Dayan & Montague, 1997).  
The intake of alcohol (and other drugs of abuse) increases DA release in the midbrain via 
disinhibition of DA neurons, liberating them from GABA neuron inhibition, which enhances 
drug intake via positive reinforcement (Di Chiara, 2002). Studies in humans and animals have 
shown that drug-related reinforcement effects exceed reinforcement effects from natural 
reinforcers such as food (Di Chiara, 2002). Since DA neurons fire in response to salient stimuli, 
the much higher effect of drugs compared to environmental events is hypothesized to alter the 
thresholds required to activate dopaminergic cells (Koob & Volkow, 2010). After chronic expose 
to alcohol, a reactive down-regulation of D2R takes place as a response to the high DA release 
during ongoing consumption (Volkow et al., 2002). This effect is also associated with increased 
relapse risk and craving (Heinz et al., 2005a). Imaging studies using (18F)-Fallypride (FAL) PET 
have shown decreased dopamine release during withdrawal and less D2/3R availability in the 
striatum in addicted patients compared to healthy controls (Heinz et al., 2004). Processes of 
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neuroadaptation take place in different regions of the brain, cumulating and influencing 
behavioural responses (see also figure 3). However, after long-term abstinence, D2/3R availability 
can recover and increase, as was shown for a small group of patients in Rominger et al. (2012).  
 
It is thought that the activation of the midbrain dopamine system includes multiple roles 
such as to give incentive salience to stimuli in the environment (Robinson & Berridge, 1993) and 
to promote performance of goal-directed behaviour (Salamone, Correa, Farrar & Mingote 2007). 
Most investigations thus focus on dopaminergic midbrain areas (such as the VTA and SNc) as 
well as the basal ganglia to which they project (in particular the ventral striatum with NAc and 
the dorsal striatum). These circuits are known to be connected to reward, conditioning and 
habituation and have been shown to be altered in AUD patients. More recently, preclinical and 
clinical studies have put an emphasis on the role of the PFC in addictive behaviour (Volkow & 
Fowler, 2000). Evidence from imaging studies showed that the transition from initial 
consumption to a chronic relapsing disease involves reprogramming of neural circuits connected 
to (1) reward and motivation; (2) memory, conditioning and habituation; (3) EF and inhibitory 
control and others (Koob & Volkow, 2010).  
A large number of functions and processes, especially higher-order EF, are ascribed to 
different regions of the PFC (see also table 4, section II.3.2.1). Thus, PFC disruption, which may 
also be mediated by dysfunctional DA projections, can help to explain the negative effects on 
behavioural and learning mechanisms in addictions such as AUD (Chen et al., 2005; Trantham-
Davidson et al., 2014; Trantham-Davidson & Chandler, 2015). As Volkow et al. (2004) 
Figure 3. Schematic Drawing describing sequential and cumulative Effects of neuroadaptive 
Changes in Addiction Development                      Retrieved and adapted from Koob &Volkow (2010) 
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postulated, decreased DA function in addicted subjects leads to decreased sensitivity to non-
drug-related stimuli (as there is less ascribed salience to natural reinforcers) and disrupts frontal 
inhibition, which both contribute to impaired control and compulsive consumption. Moreover, 
the impact of DA modulation on synaptic plasticity and its influence on LTP has been described 
in three major brain regions innervated by DA: the striatum including the nucleus accumbens, 
the hippocampus and the prefrontal cortex (Jay, 2003).  
 
II.2.1.2. Measuring Dopamine 
 
The direct investigation of DA, its signalling and metabolites in human brains brings a 
challenge with it – as measurements used in animals are often invasive (e.g. micro-dialysis or 
post-mortem brain tissue analysis). With the development of neuroimaging techniques, such as 
fMRI, MRS, PET and the use of specific (radio-) pharmaceuticals over the past decades, it has 
become easier to investigate the CNS, its neurotransmitters, metabolites and functioning in a 
non-invasive way. It is possible to investigate presynaptic (DA transporter, vesicle transporter 
and DA storage) as well as the postsynaptic DA system (Politis, 2014). For an overview of 
dopaminergic neuroimaging see figure 4. Amongst the PET radioligands for postsynaptic D2/3R 
are mainly three molecules that have been used in studies with humans and that continue to 
appear in recent research. These are 11C-Raclopride (RAC), 11C-FLB 457 and 18F-Fallypride 
(FAL). Due to its kinetics and moderate in-vivo affinity RAC is only used to display striatal 
receptor density. However, 11C-FLB 457 and FAL have higher affinity and signal-to-noise ratios 
Dopamine 
Transporter
123I-FP-CIT
123I-beta-CIT
123I-Altropane
11C-(MP)
11C-CFT
18F-CFT
11C-PE2I
18F-FP-PE2I
99mTc-TRODAT-1
11C-RTI32
Vesicle 
Transporter
11C-DTBZ
18F-DTBZ
Dopamine 
Storage
18F-Dopa
Dopamine D2/3 
Receptors
11C-Raclopride
11C-FLB456
11C-PHNO
18F-Fallypride
123I-IBZM
Figure 4. Radiotracers in dopaminergic Neuroimaging 
                                                     Retrieved and adapted from Politis (2014) 
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than RAC and can therefore provide reliable measures of extrastriatal D2/3R availability, which is 
typically much lower than in the striatum. Because of the high affinity of 11C-FLB 457, 
clearance from the striatum is relatively too slow for 11C decay, leaving a max of 2 hours for 
imaging time. Thus, FAL is the molecule most suited for investigating striatal and extrastriatal 
quantification of D2/3R availability in one imaging session (Laruelle, Slifstein, & Huang, 2003; 
Slifstein et al., 2010). More detailed information about FAL and PET/CT to investigate D2/3 
receptor availability can be found in section III.3.2 and III.3.3. 
 
 
II.3. Executive Functions 
 
As stated above, AUD is amongst other aspects characterized by the repeated intake of 
alcohol despite negative consequences (American Psychiatric Association, 2013). This 
component is possibly caused and maintained by an impaired flexibility to change and adapt 
behaviour and by impaired inhibitory control – in short by difficulties in abilities that are 
attributed to executive functioning. To gain control over adaptive behaviour, attributed values 
need to be transmitted to higher executive regions of the CNS, such as the PFC – regions 
disrupted in compulsive drug intake and involved in the development of addiction (Goldstein & 
Volkow, 2011). 
 
II.3.1. Definitions 
 
There is no universally accepted definition of what exactly falls under the term executive 
functions - only that it collects a series of many different higher-order cognitive abilities. It is a 
multifaceted neuropsychological construct that enables higher organisms to act and adjust goal-
directed behaviour. It is therefore also highly relevant for the avoidance of maladaptive 
behaviours (Day, Kahler, Ahern, & Clark 2015).  
We as humans have the most evolved EF of all species, allowing us to consider and select 
options and give specific responses to a stimulus. For this, we can take into account situational 
contexts, our long-term goals and knowledge that we previously acquired (Suchy, 2009). Making 
use of EF is however connected to a stronger effort than responding with routinized sets of 
behaviour. Thus, most of the time, even humans do not utilize EF processes but function and 
behave in well-rehearsed routines. Hence, EF remains dormant for most of the time as long as 
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automated functioning is sufficient. EF processes only take over when the novelty and/or 
complexity of the situation demands other than automatic or learned responses (Suchy, 2009) for 
example, when there is no well-established stimulus-response association, when one notices an 
error in one’s functioning or a sub-optimal behaviour (Gilbert & Burgess, 2008). The term EF 
has become synonymous with these complex networks’ abilities to supervise, update, inhibit and 
adapt behaviour (see also figure 5).  
Despite the many discussions about constructs and theories concerning the splitting up of 
EF specific abilities, there are major subcomponents of EF that can lead to certain predictable 
behavioural response patterns: (1) set formation, (2) set maintenance, (3) set shifting (Suchy, 
2009). Or as proposed in another influential model, which states that EF is comprised of three 
higher-order factors:  
(a) set shifting or also called mental flexibility,  
(b) information updating or working memory,  
(c) top-down inhibitory control, including behavioural and emotional self-inhibition and 
interference control such as in selective attention (Diamond, 2013; Miyake et al., 2000).  
 All of these subcomponents play a role in the development and maintenance of 
problematic alcohol intake and alcohol related behaviour. Other cognitive components can be 
added to this model including semantic / phonetic fluency, working memory, planning abilities, 
judgment, decision-making and insight (Kramer et al., 2014), which leads to a wide and complex 
network of cognitive abilities. A number of studies have shown the involvement of disrupted EF 
under the direct influence of alcohol (Guillot, Fanning, Bullock, McCloskey & Berman, 2010; 
Figure 5. Schematic Diagram of Executive Functioning (EF) as a 
supervisory/modulating System of Routine Behaviour 
                  Based on Norman & Shallice (1998), adapted from Gilbert & Burgess (2008) 
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Montgomery, Ashmore & Jansari, 2011) and in AUD and other SUD (Bernardin, Maheut-
Bosser, & Paille, 2014; Day et al., 2015; Fernández-Serrano, Pérez-García, Schmidt Río-Valle, 
& Verdejo-García, 2010; Soyoung Q. Park et al., 2010; Ratti et al., 2002). Others have shown 
that subjects with impaired EF may be at risk for SUD development (Nigg et al., 2006) or that 
EF performance can be a predictor for treatment outcomes (Bates, 2000).  
 
II.3.2. Neuroanatomy and Neurochemistry 
 
The construct of executive functions has its historical roots in the observation of patients 
with frontal lobe damage in the context of neuropsychological studies. For a long time, it has 
been known that patients with frontal lobe damage may present a wide range of problems 
including difficulties with the regulation of their behaviour (e.g. of impulsive actions or 
emotions), impaired functionality in everyday life, the inability to pursue long term goals or the 
dysfunctional preservation of inappropriate behaviour (Gilbert & Burgess, 2008). Thus EF has 
been traditionally associated with the frontal lobes, emerging from observations of clinical 
frontal lobe syndromes in the 1970s. Later on, EF has been particularly associated with the PFC 
(Alvarez & Emory, 2006) including all three main convexities (see figure 6): dorsolateral  
PFC, superomedial PFC (including the anterior cingulate gyrus (ACC)) and the ventral PFC 
consisting of orbitofrontal and ventromedial PFC (Suchy, 2009). With the possibility of 
Figure 6. The Human Prefrontal Cortex (PFC) 
(A) lateral view; primary (1), secondary and supplementary motor areas (2); (B) dorsolateral PFC 
(dlPFC); (C) medial view; superomedial (sm), ventromedial (vm) PFC and anterior cingulate Cortex 
(ACC), (D) ventral view; orbitofronal PFC (OFC). 
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performing functional neuroimaging, it has become clearer that EF also depends on the integrity 
of complex networks and functional connections between brain regions that rely on balanced 
 excitatory and inhibitory neurotransmitter systems. It is thus not possible to localize EF solely in 
the PFC, even if it is highly associated with it, as it is not possible to find a single anatomic 
correlate for a complex neuropsychological construct. However, a certain association between 
distinct regions and specific functions can be observed (see table 4). Therefore, EF is very 
vulnerable to various kinds of CNS injury, to perturbations in the neurotransmitter systems and 
as a result, sensitive to many psychiatric, neurodegenerative and medical conditions (Goldstein 
& Volkow, 2011). 
 
II.3.2.1. Dopaminergic Modulation of Executive Functions 
  
Many modulation processes in the PFC take place via projections of monoaminergic 
neurons, including dopaminergic neurons. These projections reach out widely to diverse areas, 
including the hippocampus, striatum, amygdala, thalamus and the neocortex (Robbins & 
Arnsten, 2009). Especially the field of working memory has been studied in this context, but also 
other subcomponents of EF have been the centre of investigations (Floresco & Magyar, 2006). 
Multiple studies have been performed, looking into rodents, primates and humans. Different 
types of study designs have been used, from observations to interventional studies and genetic 
analyses. In particular in recent years, PET studies in humans have shown an inverted-U-shape 
relationship between D1R binding in the PFC and the performance in EF tests (Takahashi et al., 
2008; Vijayraghavan, Wang, Birnbaum, Williams, & Arnsten, 2007) such as the Wisconsin Card 
sorting test (WCST), a laboratory measure that reflects in particular shifting abilities and mental 
flexibility. The inverted-U relationship suggests that levels, which lie either above or below the 
optimum level of dopaminergic activation, lead to impaired performance. Experiments with 
rodents and monkeys have also shown impaired cognitive functioning in laboratory measures 
(especially in spatial working memory) after the injection of selective D1R blockers into the PFC 
but not always after the injection of D2R blockers (Floresco, Magyar, Ghods-Sharifi, Vexelman 
& Tse, 2006; Granon et al., 2000; Sawaguchi & Goldman-Rakic, 1994). The review by Robbins 
and Arnstern (2009) summarizes and suggests a major role of DA modulation in a set of 
different tasks of the PFC: spatial and online working memory, reversal learning/extinction and 
underlying reinforcement learning. As described by Seamans & Robbins (2010) and Floresco & 
Magyar (2006), D1R and D2R can be stimulated optimally at different 
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Table 4. Processes associated with the Prefrontal Cortex that can be disrupted in Addiction  
Retrieved and adapted from Volkow et al., 2011. 
PFC = Prefrontal cortex; mPFC = medial PFC; DLPFC = dorsolateral PFC ; vmPFC = ventromedial prefrontal cortex; vlPFC = 
ventrolateral PFC; ACC = anterior cingulate cortex; rACC = rostral ACC; dACC = dorsal ACC; IFG = inferior frontal gyrus; OFC 
= orbitofrontal cortex; lOFC = lateral OFC; mOFC = medial OFC 
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 levels of DA presynaptic activity. This may improve different aspects of cognitive abilities. The 
distinct role of D2R levels in this context is less clear and needs further investigation. However, 
D2/3R availability in the striatum has been positively associated with performance on laboratory 
tests that reflect and rely on EF (Ballard, Dean, Mandelkern & London, 2015; Chen et al., 2005; 
Christopher et al., 2014). As striatal D2/3R availability is typically lower in AUD patients than in 
healthy controls (Bühler & Mann, 2011; Heinz, Siessmeier, et al., 2005b) we can suppose that 
there are also extrastriatal effects of chronic alcohol consumption on D2/3R availability. This is of 
special interest in areas that are connected to EF and prefrontal integrity. The relation of D2R 
availability in the frontal cortex and EF has been shown for example by Vyas et al. (2017) for 
schizophrenic patients. Better performance in WCST perseverative errors was associated with 
higher binding potential in the frontal cortex. 
 
II.3.3. Assessing Executive Functions 
 
 The variety of laboratory tests that investigate EF performance is as inhomogeneous as 
the different theories that try to define what EF is. Thus, a large variety of tests have been 
developed and implicated (Day et al., 2015). Some of them have gained greater acceptance in the 
researcher community and have been used and validated intensely. The tests administered in this 
study will be further explained in the methods section (see III.2.2). 
 
II.4. Alcohol and Executive Functions 
 
As proposed by Koob and Volkow (2010), a possible chronologic development of 
addiction can be seen as a change in firing in mesolimbic DA neurons starting with 
administration of the drug (e.g. alcohol), leading to LTP first in the VTA and then in the NAc 
and engaging the dorsal striatum via feedback loops. Long-term changes in the extended 
amygdala and the PFC may follow (see figure 3). This eventually leads to a continued strong 
drive for drug-seeking behaviour, reduced inhibitory control and poor decision-making when 
confronted with alcohol related stimuli even long after withdrawal. Studies in humans and 
animals have shown that alterations in DA signalling play a part in higher relapse risks, stronger 
craving and impaired quality of life (Heinz, Siessmeier et al., 2005b; Volkow et al., 2002). On 
the contrary, individuals with higher levels of D2R availability and a positive family history of 
AUD may have a protective factor towards the development of AUD (Volkow et al., 2006). 
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When talking about EF in AUD a question of causality is inevitable: Does impaired EF lead to 
compulsive alcohol consumption or does drug consumption lead to EF difficulties? The 
interconnection between the two is evident but it is not possible to develop an exclusive 
hierarchic or chronological causality. However, there seem to be certain patterns and regularities 
in the impairment of EF under the acute and chronic influence of alcohol. In the following, we 
will focus on aspects of EF that may have a strong impact on AUD and on those that are most 
affected by alcohol consumption.  
 
II.4.1. Acute Alcohol intake and Executive Functions 
 
The direct influence of acute alcohol intake on EF in healthy subjects has been 
intensively investigated. These studies help to understand dose- and task-related effects of 
ethanol on the brain. Additionally, they contribute to identifying the affected functions and brain 
circuits impaired by acute intoxication. It has been shown that temporary impairments of EF 
occur in different laboratory measures for set shifting, information update, working memory and 
response inhibition (see Day et al., 2015). The review by Day et al. (2015) lists 35 studies that 
investigate the acute effects of alcohol on EF. Examinations throughout the studies reviewed 
took place under different conditions, between 0.2 and 0.8g ethanol per kg bodyweight or at 0.01 
to 0.10% BAC. As summarized by the authors, many sub-functions such as long- and short-term 
memory, working memory, word generation, mental flexibility, response inhibition and reaction 
time were affected by acute alcohol intake. The effects occurred mainly in groups with high and 
medium BAC, leading mainly to perseveration errors that are thought to be more specific to 
frontal lobe dysfunction. 
 
II.4.2. Chronic Alcohol intake and Executive Functions 
 
 A characteristic trait of AUD and chronic, hazardous alcohol consumption is e.g. a 
certain loss of control over the amount of alcohol that is taken in or the resulting personal 
problems. In the most pronounced cases of AUD, persistent consumption can lead to substance-
induced neurocognitive disorders such as the Wernicke-Korsakoff syndrome (WKS) – with 
extensive impairment and damage especially to the frontal lobe and important associated 
functions such as EF (Oscar-Berman, Kirkley, Gansler, & Couture, 2004). The investigation of 
chronic alcohol intake and its influence on EF performance brings up different challenges. The 
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influencing factors are by far not as controllable as in studies that investigate the acute influence 
of alcohol consumption. In those studies, researchers have direct insight and control over e.g. 
applied doses of alcohol. Investigations of chronic alcohol intake however depend on self-rating 
and personal insight abilities as well as the willingness of the participants to give honest 
information about aspects such as consumption patterns and alcohol-related problems. In the 
following, we will focus on two subgroups of chronic alcohol consumption: (1) heavy drinking, 
HR subjects with a problematic intake of alcohol as defined in chapter II.1.1.2 and (2) patients 
with a diagnosis of AUD after acute detoxification.  
 
II.4.2.1. High-Risk Drinking and Executive Functions 
 
 In a study published by Heffernan (2002), HR alcohol users reported more memory slips 
of prospective, short-term and long-term memory than controls, suggesting that heavy drinking 
has a negative effect on aspects of everyday memory. As shown in the review by Montgomery et 
al. (2015), many studies that are investigating HR drinking behaviour and EF concentrate on 
young subjects in their early twenties, who are mainly university students and currebtly 
performing HED. Those subgroups present a very specific group of HR subjects, not fully 
representative of the community. Other studies, as the one performed by Houston et al. (2014), 
however, looked into bigger samples (n=560 subjects) with differing educational backgrounds, 
different age groups and thus representing a demography more similar to that of the community. 
The results of that study showed that greater alcohol use was associated with significantly poorer 
performance in EF tasks such as WCST, TMT (testing mental flexibility and set shifting ability), 
go/stop tasks (testing response inhibition) and higher scores in a self-reported dysexecutive 
functioning questionnaire. This effect remained when controlled for age, gender and education 
(Houston et al., 2014) and is providing evidence that HR drinking behaviour has a negative 
impact on EF performance. 
 
II.4.2.2 Alcohol Use Disorder and Executive Functions 
 
 A large number of studies investigating AUD and the influence of alcohol on the brain 
have been performed over the past decades. Studies of neuropathology, post-mortem and in vivo 
neuroimaging using CT and MRI have found global atrophy and structural abnormalities in the 
CNS of AUD subjects. Furthermore, there is a great body of work showing that alcohol-
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dependent subjects exhibit particular deficits, involving alterations in brain circuits connected 
with the prefrontal cortex, cognitive abilities and EF (Moselhy, Georgiou, & Kahn, 2001; Oscar-
Berman & Marinković, 2007; Stavro et al., 2013; Wilcox, Dekonenko, Mayer, Bogenschutz, & 
Turner, 2014). Additional evidence in support of frontal system dysfunction in AUD is based on 
work looking into patients with persisting substance-induced amnestic disorder such as WKS 
(Oscar-Berman & Evert, 1997; Oscar-Berman, Kirkley, Gansler & Couture, 2004; Sullivan, 
Harris & Pfefferbaum, 2010). 
 Taking these deficits in working memory, set maintenance, response inhibition and 
mental flexibility into account, subjects with AUD are challenged in a particular way concerning 
everyday living, employment situations and personal life. Long-term abstinence from alcohol 
can improve or resolve previously present deficits in cognitive and EF (Guthrie & Elliott, 1980; 
Oscar-Berman et al., 2014). However, not all AUD patients show EF impairment. The 
exploration regarding which processes are spared and which are affected in a given subject might 
give a basis for a more targeted therapy approach during recovery (Sullivan et al., 2010).  
 
Normalizing these functions [reduced inhibitory control, emotional disruptions], 
using empirically based and targeted pharmacological and cognitive-behavioural 
interventions — in combination with the relevant reinforcers — should become a 
goal in the treatment of addiction. (Goldstein & Volkow, 2011) 
 
 
 
II.5. Hypotheses 
 
Regarding the development and maintenance of problematic alcohol consumption and 
AUD, it is important to look into different subgroups to simulate the dimensional approach of the 
disorder. Therefore, the inclusion of a third group that lies between the two extremes on the 
continuum was plausible.  
We aim to determine the relationship between D2/3R availability and EF performance 
with a special focus on group differences between LR, HR controls and AUD. Non-displaceable 
binding potential (BPND) of FAL and EF test results will be compared between the three groups 
of subjects. 
 
Hypothesis 1.1 (H1.1) 
EF performance of HR controls and detoxified AUD patients is impaired when compared to LR 
control performance. 
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Hypothesis 1.2 (H1.2) 
HR subject will lie on an intermediate performance level between LR and detoxified AUD. 
 
Hypothesis 2.1 (H2.1) 
Extrastriatal D2/3R availability is lower in detoxified AUD than in LR and HR controls. 
Hypothesis 2.2 (H2.2) 
Extrastriatal D2/3R availability measured in HR subject will lie on an intermediate level between 
LR and detoxified AUD. 
 
Hypothesis 3 (H3) 
Extrastriatal D2/3R availability is positively correlated to EF performance. 
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III. Material and Methods 
 
The present study was performed as a subproject (Project 5 (P5)) of the LeAD Study, a 
bi-centric study on learning and habituation as predictors of the development and maintenance of 
alcoholism (www.leadstudie.de; clinical trial number: NCT01679145). The research was 
conducted in the framework of a collaboration of Charité Universitätsmedizin Berlin and 
Technische Universität Dresden. P5 was conducted at the Clinic of Psychiatry and 
Psychotherapy at Charité Berlin and was further carried out at Physikalisch-Technische 
Bundesanstalt Berlin (PTB). The LeAD study was funded by Deutsche Forschungsgesellschaft 
(DFG FOR16/17).  
The data for P5 were collected in Berlin only. Data storage was centralized and organized 
in Dresden in a subproject of the LeAD study (see figure 7). P5 was approved by the local ethics 
committee, performed according to the World Medical Association Declaration of Helsinki and 
carried out under Prof. Dr. med. Gallinat’s and Prof. Dr. med. Felix Bermpohl’s supervision. 
Participants underwent written informed consent and detailed instruction regarding clinical 
testing and scanning procedure by trained researchers, in particular with regard to imaging 
procedures and a radiation exposure of approximately 5.8 mSv during PET/CT. All participants 
were financially compensated after their participation.  
Figure 7. Learning and Alcohol (LeAD) Study with Subprojects, Funding Period I 
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III.1. Subjects  
III.1.1. Recruitment, Inclusion and Exclusion Criteria 
 
The aim was to recruit 20 participants for each group (20 AUD, 20 HR, 20 LR). AUD 
subjects were recruited during acute detoxification on specialised psychiatric wards in four 
different hospitals in Berlin (Sankt Hedwig Krankenhaus, Bundeswehr Krankenhaus, Jüdisches 
Krankenhaus, Charité Universitätsklinikum Campus Mitte (CCM)). Patients had been diagnosed 
with AUD by independent psychiatrists and information about the LeAD study was obtained 
during inpatient treatment. AUD patients were referred to P5 from Project 2 (P2) of the LeAD 
Study. AUD diagnosis was verified through a structured clinical interview performed during the 
first assessment session in P2 by trained researchers. HR and LR controls were directly recruited 
from the community via advertisements in supermarkets, local newspapers and online on an 
internet platform (www.ebay.kleinanzeigen.de).  
Participants were screened for exclusion criteria via telephone or in person. Exclusion 
criteria were left-handedness, insufficient knowledge of the German language, major visual or 
auditory impairments, a history of any substance dependence or current substance use other than 
alcohol. Only nicotine dependence in HR and LR controls and nicotine and alcohol dependence 
in AUD patients were accepted. The AUDIT (see III.2.1.) was performed during the telephone 
screening and allowed direct allocation of controls to the HR subgroup. However, some LR 
participants were directly referred to us by P2 and did not complete AUDIT during the 
screening. Additionally, major non-communicable diseases such as non-treated diabetes, high 
blood pressure, thyroid dysfunctions and infectious diseases like HIV or hepatitis as well as 
major psychiatric disorders (lifetime history of DSM-IV bipolar or psychotic disorder; current 
threshold DSM-IV diagnosis of any following disorders: current major depressive disorder, 
generalized anxiety disorder, posttraumatic stress disorder, borderline personality disorder, or 
obsessive-compulsive disorder), intake of psychotropic medication, neurological diseases like 
epilepsy, multiple sclerosis, any form of dementia, WKS, history of traumatic brain injury, 
meningitis, brain operations or claustrophobia led to exclusion.  
AUD patients, furthermore, were to be assessed in early abstinence, i.e. between 72 hours 
and 21 days after their last drink, and only allowed to show a low severity of withdrawal 
symptoms according to the Clinical Institute Withdrawal Assessment Scale (CIWA <8) at 
baseline. As P5 was performing magnetic resonance imaging and spectroscopy (MRI/MRS) and 
PET/CT on participants, metallic implants such as pacemakers, orthopaedic or complex dental 
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prostheses and metal clips, pregnancy and nursing infants (for females), recent exposure to 
radiation (e.g. x-ray exams or CT scans in the last 3 months), were further exclusion criteria. 
Moreover, we carefully tried to match participants to minimize group differences and respected 
the inclusion and exclusion criteria.  
 
III.1.2. Group Distinction  
 
The AUDIT was used to distinguish between HR and LR control groups. A subject with 
an AUDIT score of 8 or higher and no history of a former or current AUD diagnosis or treatment 
was considered as belonging to the HR group. Subjects with a score of less than 8 or no intake of 
alcohol were classified as LR subjects. For detailed information on the AUDIT, see section 
III.2.1. 
 
III.1.3. Description of the Sample 
 
58 subjects completed the whole test battery and were included in the final sample. A 
total of 96 subjects (31 AUD; 32 HR; 33 LR) were initially recruited. A number of participants 
did not respond in verbal or written form after the first (2 drop outs) or second assessment (26 
drop outs). For study process, see figure 8. Also, a number of participants could not be assessed 
due to problems with tracer synthesis. 
Figure 8. Study Process and Participant Numbers 
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Our final PET sample consisted of 19 LR controls aged between 30.8 and 61.8 years 
(Meanage in years = 45.22; SDage = 8.65), 19 HR controls between 26.8 and 57.6 years (Meanage 
in years = 42.89; SDage = 9.08) and 20 patients between 29.4 and 58.3 years (Meanage in years = 
45.36; SDage = 8.41). Female subjects were distributed over the different subgroups as follows: 3 
LR controls, 2 HR controls and 3 AUD patients. Kruskal-Wallis tests showed no significant 
group differences concerning age, gender distribution, handedness, BMI, education years and 
estimated intelligence quotient (IQ) at baseline. Significant differences in OCDS, H(2) = 26.73, 
p < .05; ADS, H(2) = 31.91, p < .05 and AUDIT, H(1) = 13.40, p < .05, were confirmed. For 
Table 5. Descriptive Statistics of final PET Sample 
ADS = Alcohol Dependence Scale; AUD = alcohol use disorder; AUDIT = Alcohol Use Disorder Identification Test; BL = baseline; 
BMI = body-mass-index; EHI = Edinburgh Handedness Inventory; FTND = Fagerström Nicotine Dependence Scale; IQ = Intelligence 
Quotient; M = Mean; max = maximum; min = minimum; MWT-B = Mehrfach-Wortschatz-Intelligenztest; OCDS = Obsessive 
Compulsive Drinking Scale; PET = Positron Emission Tomography; SD = standard deviation. 
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visual and comprehensive reasons clinical parameters of the sample are shown for all groups 
(LR, HR, AUD) in table 5.  
 
III.2. Assessment 
 
Subjects meeting inclusion criteria were invited to Charité Berlin to complete in-person 
interviews, paper and pencil tests as well as digital questionnaires and tests during their first 
appointment. Directly prior to testing, all participants were screened for alcohol and other 
substance consumption (including benzodiazepines, amphetamines/MDA, metamphetamines/ 
MDMA/XTC, opiates, cannabis) via breath and urine test (Mahsan® – Kombi/DOA6 
Schnelltest, Mahsan® Diagnostika, Germany) and were only allowed to complete the assessment 
if tested negative. A positive test led to direct exclusion. All participants had their blood taken 
for future genotyping and further analysis before starting the session. The assessments took place 
during the day in special testing rooms at Sankt Hedwig Krankenhaus Berlin (between 2014 and 
2015) and CCM (from 2013 until 2016). Participants were allowed to take breaks when needed. 
Supervision and explanation of tasks was ensured through the presence of at least one and a 
maximum of two study researchers. Assessments took place at least one day before the imaging 
assessments. Participants were contacted after a 6 months’ interval for a first telephone follow-
up (FU). For the 12-month-FU, we invited the subjects once again to Charité Berlin to let them 
perform a similar battery of tests. The last 12-month-FUs were completed in 2017.  
The completion of the battery of questionnaires, neuropsychological and cognitive tests 
took between two and a half and three hours on average. All three groups were equally assessed 
in different domains of executive functioning and cognitive performance. Subjects participating 
in Project 2 additionally completed the WHO composite international diagnostic interview 
(CIDI), adding another 60 minutes to the session.  
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III.2.1. Clinical Tests 
Alcohol Use Disorder Identification Test (AUDIT) 
The AUDIT has been widely used and verified as a reliable tool of early detection of 
problematic alcohol consumption in a primary healthcare setting (Saunders, Aasland, Babor, de 
la Fuente, & Grant, 1993). It is a simple questionnaire that comprises 10 items concerning 
drinking behaviour, alcohol consumption and related problems such as domestic, legal or 
occupational difficulties related to the consumption of alcohol. For each response, there is a 
minimum of 0 and a maximum score of 4 points, thus a total minimum of 0 and maximum score 
of 40. A positive case, as described by Saunders et al., was defined as any of the following: a 
hazardous daily level of alcohol intake (meaning an average intake of 40 g of pure ethanol for 
women and 60 g for men), recurrent intoxication (with an intake of 60 g of ethanol daily or 120 g 
weekly), abnormal drinking behaviour (meeting at least one of the criteria of the alcohol 
dependence syndrome but not enough to fit its diagnosis), at least one alcohol-related problem in 
the past year (e.g. traumatic injury caused by intoxication, drunk-driving), an alcohol-related 
disease or a perceived drinking problem (for example concern mentioned by family, health 
professionals or friends).  
The cut off scores were chosen to fulfil maximal sensitivity and specificity and thus set at 
a score of 8, resulting in an overall sensitivity of 92% for identifying hazardous and harmful 
alcohol consumption and a specificity of 94% (Conigrave et al., 2006; Saunders et al., 1993). 
Reliability and validity were tested in different population samples from primary health care 
settings in the USA, Kenya, Australia, Bulgaria, Norway and Mexico (Saunders et al., 1993). We 
used a German translation of the AUDIT (Rist et al., 2003). 
 
Alcohol Dependence Scale (ADS)  
The ADS is a widely used, valid and reliable clinical and research tool which provides a 
quantitative measure of AUD severity (Skinner & Allen, 1982). The total of 25 items cover 
domains such as impaired control over drinking, awareness of compulsive behaviour, increased 
tolerance, withdrawal symptoms, salience of drink-seeking behaviour and refer to the past 12 
months. The ADS can be used to quantify the severity of AUD with respect to treatment 
planning for patients but also as a screening tool. A score of 9 or more on the ADS is highly 
predictive of a DSM / ICD diagnosis of AUD. We used a German translation of the ADS 
questionnaire (Ackermann, Hollweger & Gordon, 1999). The computer self-administration took 
about 5 minutes.  
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Obsessive Compulsive Dependence Scale (OCDS) 
The 17-item OCDS is a quick and reliable self-rating instrument that assesses compulsive 
behaviour with regard to drinking and obsessive thoughts about alcohol that are thought to be 
crucial dimensions of perceived craving (Anton, Moak & Latham, 1995). This scale has been 
shown to be sensitive to and specific for the obsessive and compulsive characteristics of 
drinking-related thought in alcohol-abusing and AUD populations. It is also possible to calculate 
subscores concerning obsessions and compulsions as suggested by Anton et al. (1995). 
Furthermore, it has been shown to be sensitive as a monitoring tool with predictive validity for 
relapse drinking. We used the German translation according to Mann & Ackermann (2000) in a 
computed version for self-administration, taking about 5-10 minutes. 
 
Fagerström Nicotine Dependence Scale (FTND)  
The FTND is a standard test to evaluate physical nicotine dependence and provide an 
ordinal measure of severity (Heatherton, Kozlowski, Frecker & Fagerström, 1991). The answers 
to the 6 items add up to a total score of between 0 and 10 points. We used the German translation 
according to (Bleich, Havermann-Reinecke, & Kornhuber, 2002) to determine smoking-status. 
 
Edinburgh Handedness Inventory (EHI) 
The EHI is a self-administered measurement scale that is frequently used to assess the 
dominance of a person's right or left hand (laterality) (Oldfield, 1971). The items cover everyday 
activities. We used our own translation of the EHI to assess handedness with 8 items. All 
participants with results of strongly right-handed and mixed right-handed were attributed right-
handed, persons strongly left-handed and mixed left-handed were considered as left-handeder. 
 
Estimated IQ – Mehrfachwahl-Wortschatz-Intelligenztest 
Verbal intelligence was assessed by a very common standardized, multiple choice 
vocabulary test (Mehrfachwahl-Wortschatz-Intelligenztest (MWT-B)) as a representative 
measure of fluid intelligence. The results are known to correlate fairly well with global IQ levels 
in healthy adults and to be rather insensitive to confounders such as age, CNS and psychiatric 
diseases (Lehrl, 2005). Its administration takes about 5 minutes. Subjects are asked to identify 
the correct word out of a group of words that are phonetically similar. However, only one of the 
given words in each of the 37 groups is correct. The items are listed in ascending order in terms 
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of their difficulty. Thus, in the interpretation of the test, the further the participant gets in 
identifying the right word, the higher the crystallized intelligence. Estimated IQ levels were 
examined to control for major differences between groups that can reflect on cognitive and EF 
test performance. 
 
III.2.2. Cognitive Tests – Assessing Executive Functioning 
 
As stated in section II.3.3., many different laboratory tests have been developed to assess 
EF. For this study, we chose to use a battery of tests that are well known and easy to perform. 
We administered the battery of neuropsychological tests and questionnaires during the first 
testing session. Only tests and questionnaires relevant to this investigation will be explained in 
the following. 
 
Semantic Fluency – Animal-naming (CIMP) 
 Fluency represents the ability to maximize the production of information in a limited time 
span while the subject must avoid repetition. Semantic fluency (or category fluency) is one of 
three common fluency tasks along with design (e.g. to connect dots with four lines in as many 
different ways as possible) and phonemic fluency (e.g. to generate as many words as possible 
starting with a certain letter). During this task, participants were asked to name as many words 
from a specific category (e.g. animals, clothes, groceries) as possible. The limited timespan for 
the task was 60 seconds. In the end, the score reflects the number of correctly named animals in 
the given timespan. Deficits observed in these measures can be a sign of disorganization, lack of 
initiation (Rabinovici, Stephens, & Possin, 2015) and reflect thus on EF. 
 
Trail-Making Test (TMT) Part A+B 
The trail-making test (TMT) has been widely used for the assessment of cognitive 
impairment (Reitan, 1955). In particular, it has been used to look into alcohol abuse and frontal 
lobe (dys)function. The TMT is a tool to measure visual attention, motor speed and set 
shifting/cognitive flexibility. In TMT-A, the participant has to draw a line between a series of 
numbers, connecting them in the correct sequential order as fast as possible. Part B requires the 
participant to draw a line connecting numbers and letters in alteration between the ascending and 
the alphabetical order (1-A-2-B-3-C-...). Thus the participant needs to additionally cope with a 
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shifting paradigm, divide the attention between numbers and letters and suppress the impulse to 
follow the more familiar task of connecting numbers in the sequential order only. Various 
studies have shown that especially the performance in TMT-B can be impaired in AUD patients 
(Houston et al., 2014; Ratti et al., 2002; Zinn, Stein & Swartzwelder, 2004) even in those that 
did not show any obvious deficits during clinical observation or in everyday life (Moselhy et al., 
2001). Also the performance of HR subjects as described in Houston et al. (2014) can be poorer 
when compared to LR controls. 
 
Digit Symbol Coding (ZST) 
 The ZST is a subcomponent retrieved from the Wechsler Adult Intelligence Scale 
(WAIS) (Aster, von Neubauer & Horn, 2006) that investigates mainly working memory and 
processing speed. During ZST, participants are asked to translate a sequence of numbers (from 1 
to 9) corresponding to digit-symbol pairs as shown at the top of the given work sheet. Subjects 
are asked to work as fast and as precise as possible. The number of symbols correctly written 
down in a limited time (120 seconds) is measured. This test reflects mainly processing speed and 
working memory abilities.  
 
Digit Span Backwards Test (ZNR) 
The ZNR mainly investigates working memory and is also retrieved from the WAIS 
(Aster, von Neubauer & Horn, 2006). For ZNR, subjects hear a sequence of numerical digits at 
approximate speed of one digit per second and are asked to repeat the sequence in reverse order. 
After a correct answer, the length of the sequence increases. The longest span of correctly 
repeated digits is measured. Points for each correct sequence are added up to measure 
performance.  
  
 43 
III.3. Imaging Acquisition 
 
All participants underwent two imaging assessments on two separate days after the 
clinical assessment. FAL PET/CT took place at Charité Berlin and MRI/MRS at the Physikalisch 
Technische Bundesanstalt Berlin (PTB). MRS data were not analysed for this particular work. 
PET measurements were performed in cooperation with the department of Nuclear medicine of 
Charité Berlin (for radiochemistry, synthesis of the tracer and scanning procedure). For this 
analysis, the focus will be on acquired PET/CT and structural MRI data. Participants started their 
PET session either at 9 or 10.30 a.m. during weekdays. The whole scanning process took up a 
maximum of 5 hours. PET/CT data was acquired in 3 blocks with a break between each block 
during which participants were allowed to stretch, drink, eat and use the bathroom. Trained 
medical personnel were present throughout the exam. Subjects participating in P2 also 
underwent functional magnetic resonance imaging (fMRI) beforehand. 
 
III.3.1. Magnetic Resonance Imaging 
 
Anatomical MRI data was obtained during the second session at PTB prior to PET/CT 
testing. The whole session lasted approximately 1.5 hours. MRI was carried out on a 3-Tesla 
scanner (Siemens Verio) using a circularly polarized head coil. T1-weighted images (modified 
driven equilibrium Fourier transform (MDEFT), echo time (TE) = 3.8 ms, repetition time (TR) = 
20.53 ms, 128 contiguous slices of 1.5 mm thickness, 1 mm inplane (x-y) resolution) were 
acquired. MRI was not one of the primary measurements and will thus not be explained in detail 
in the present work. 
 
III.3.2. Positron Emission Tomography – Principle and Physical Basis 
 
PET is a type of nuclear medical imaging and provides information that is not available 
through other procedures. It is used in diagnostics and research to assess metabolic processes in 
the body and to investigate a multitude of biochemical and physiological parameters. In contrast 
to classical x-ray examinations or CT it does not generate images by passing x-rays though the 
body from an external source. PET scanners detect pairs of photons (gamma (γ) rays) that are 
emitted by a special positron-emitting radioactive tracer from inside the body. In PET images, 
areas of greater intensity, so called hot spots, indicate a higher concentration of the tracer and 
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thus higher metabolic or chemical activity. Corresponding to that, areas with low intensity 
represent less activity and less accumulation and are thus called cold spots (Mikla & Mikla, 
2014). The assessment of different parameters is possible due to different tracers. Nearly all 
biological molecules (e.g. glucose, amino acids, peptides, enzymes, transporters, receptors, 
proliferation markers etc.) can theoretically be labelled with positron emitters (Wadsak & 
Mitterhauser, 2010).  
Therefore, the application (intravenous, oral, inhaled) and choice of a 
radiopharmaceutical plays a central role in the selectivity and functioning of PET. 
Radiopharmaceuticals are specific molecules that are radiolabeled and thus consisting of two 
essential parts:  
(a) a molecular structure (vehicle or ligand) that determines the distribution and target 
site inside the organism according to its binding characteristics, pharmacodynamics and 
pharmacokinetics  
(b) a radioactive, positron-emitting isotope which is responsible for the signal that allows 
tacking from outside the organism via PET (Wadsak & Mitterhauser, 2010).  
Isotopes are variants of a chemical element that differ in the number of neutrons in their 
atomic nucleus. Proton numbers stay the same, as they define the chemical element. Isotopes 
used for PET typically hold an excess of protons compared to neutrons in their nucleus as these 
typically decay to a large portion in beta plus (β+) decay. By definition, the atomic nucleus emits 
a positron (e+) and a neutrino during β+ decay in order to transform a proton into a neutron. In 
that way, the atom reaches a more stable configuration. The neutrino does not interact with 
surrounding tissue, whereas the e+, being the antiparticle of an electron (e-), has a positive charge 
and interacts with an e- of another atom. When e+ stops moving away from its source and meets 
an e-, their entire rest mass energies (511 keV each; 1,22 MeV in total) are fully transformed into 
two photons travelling at an 180° angle in opposite directions (Mikla & Mikla, 2014). This 
process is called annihilation coincidence. The simultaneous detection of the two emerging 
photons, the annihilation coincidence detection (ACD), is the basis of PET (see figure 9). The 
emission of photons is by definition γ-radiation and can, in contrast to e+, leave the body. 
Surrounding detectors inside the PET scanner can register the emitting γ-rays. The site of the 
annihilation has to be close to or on the line that is projected by the two photons (line of 
projection, LOP). Its distance to the LOP is defined by the energy of the e+ and is a limiting 
factor to the precision of PET resolution. PET cameras can have up to thousands of opposing 
detectors to localize the annihilation processes as precisely as possible.  
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Radiopharmaceuticals cannot be chemically distinguished from their physiological, non-
radioactive counterpart and are thus processed and transported indifferently to them in the body 
(Wadsak & Mitterhauser, 2010). Usually, the amount of applied tracer is very low so that 
physiological processes are not impaired. This particularity makes it possible to visualize 
metabolisms and processes in vivo and track the substance throughout the body. Various 
radiotracers are being used in different fields of nuclear medicine. A widely known tracer is 18F-
fluorodeoxyglucose (18F-FDG), which is used mainly in oncology to show processes with 
increased metabolism like cancers. The isotope 18fluorine (18F) holds one neutron less than the 
naturally occurring, stable isotope 19F. It has a half-time of 110 minutes and is produced either 
onsite in cyclotrons or can be distributed regionally and is thus very convenient for clinical 
exams (Muehllehner & Karp, 2006). By losing a proton, it is transformed into 18oxygen (18O) – a 
more stable and naturally occurring isotope of oxygen, the preceding element in the periodic 
table of the elements with one proton less in its core than fluorine. This transformation happens 
through  β+ decay, the atom emits an e+ and a neutrino and thus loses a proton from the atomic 
nucleus. The annihilation process of the emitted e+ and an e- in the surrounding tissue transforms 
their masses into two photons travelling in opposite directions, as mentioned above. These can 
be detected by the PET scanner and provide information about their origin. 
Figure 9. Schematic Illustration of Annihilation Coincidence Detection (ACD).  
An event is only counted when the two γ-rays are detected simultaneously (within the timing 
window); C1 and C2 are the single count rates recorded by Detectors 1 and 2.  
                                                                    Retrieved and adapted from Mikla & Mikla, 2014 
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 If two photons are detected by opposing detectors within the coincidence timing window 
τ (typically 6 to 12ns = 6 to 12 x 10-9s), they are assumed to emerge from the same annihilation 
event and are called a true coincident event. Such a definite time window is needed, as photons 
have slightly different distances to travel until they reach the detector, depending on the exact 
localization of the positron-electron annihilation. However, as photons travel at the speed of 
light, this effect is however very small. Photons within a relatively large energy range (e.g. 250–
650 keV) can be detected as valid γ-rays emerging from an annihilation. This may produce 
mispositioned coincidence events. It should also be noted that not all photons can be detected by 
the PET camera. Some photons travel in other directions than in that of the detectors or are 
altered in their direction, others are absorbed by the surrounding tissue. It is also possible that 
two photons are accidently registered as emitting from the same annihilation process due to very 
little time differences but do not do so (Compton-scattered annihilation, scattered γ-rays, 
scattered and unscattered non-annihilation photons). These processes affect the quality and 
resolution of PET images. The integrated data result in tomographic images that can be 
reconstructed with algorithms similar to those used for 3D CT image reconstruction. The spatial 
resolution of the detectors and the kinetic energy of the e+ limit the total special resolution of 
PET to 1-2 mm in humans (Mikla & Mikla, 2014).  
 
PET data can be combined with anatomical data from MRI or CT. In PET/CT, the 
sequentially registered images are taken in one session to be then superposed on a set of 3D 
images. The alignment of functional (PET) and anatomic data (CT/MRI) allows much higher 
precision of anatomic localization of a hot spot (a metabolically active process). The merging of 
MRI and PET data from two different sessions is possible as well. In this study, we used MRI for 
anatomical data and PET for quantitative characterization of the dopamine D2/3R status. It was 
performed using a time-of-flight PET/CT system Philips Gemini TF 16 (Surti et al., 2007). The 
high-affinity ligand FAL will be discussed in more detail in the section below. 
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III.3.3. 18F-Fallypride - showing D2/3 Receptor Availability 
 
 
The molecule FAL, as shown in figure 10 above, is a substituted benzamide and a high-
affinity D2/3R antagonist and radioligand. Its affinity for other receptors such as D4R is poor 
(Mukherjee et al., 2002). It is thus used for quantitative characterization of D2/3R availability 
with PET. Due to its high affinity and relatively rapid in vivo reversibility of binding, it can 
simultaneously provide information about postsynaptic D2/3R binding in extrastriatal brain 
regions with low receptor density and in the striatum with high receptor density in the same 
scanning session. However, the ligand clears slowly from areas with a high receptor density. 
Scanning therefore has to be performed up to 4 hours after the application of FAL to be able to 
trace emission during the wash-out phase in the striatum (also see scanning process, figure 11). 
To bind to the postsynaptic DA neuroreceptors, the tracer molecules compete with endogenous 
DA in the brain (Laruelle, 2000). 
The FAL that was used for this study was produced at the Department of Nuclear 
Medicine of Charité Berlin following protocols previously described by Mukherjee, Yang, Das 
& Brown (1995). For detailed information about production and development processes, 
kinetics, distribution, sensitivity and advantages, see primary literature (Laruelle et al., 2003; 
Mukherjee et al., 2002, 1995; Slifstein et al., 2010) as this would exceed the scope of the present 
work.  
 
 
O
O
O
N
H
18F
N
Figure 10. Molecular Structure of 18F-Fallypride (C20H29FN2O3) 
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III.3.3.1. Non-displaceable Binding Potential and the Simplified Reference Tissue Method 
 
The outcome parameter of our measurements was the non-displaceable binding potential 
(BPND) of FAL. The binding potential (BP) is a combined measure of (a) the density of available 
(free) neuroreceptors and (b) the affinity of a ligand to that specific receptor. As described in 
Innis et al. (2007), BPND refers to the ratio at equilibrium of a specifically bound radioligand to 
that of non-displaceable radioligand in tissue. It is the typical measurement of reference tissue 
methods, as it compares the concentration of radioligand in receptor-rich to receptor-free 
regions. The specific binding of a radioligand equals the distribution volume of total ligand 
uptake in tissue (VT) minus the distribution volume of the non-displaceable compartment (VND). 
The volume of VND is defined as free ligand in tissue plus non-specific binding in tissue. Thus, 
BPND can also be calculated from volumes of distribution measured with arterial plasma 
concentrations of the radioligand (Innis et al., 2007) and is defined as the following:  
 𝐵𝑃!" = 𝑉! − 𝑉!"𝑉!" =  𝑉!𝑉!" − 1 
 
The unit of BP is ml/cm3. To estimate BPND, a reference tissue is needed. This tissue needs to 
have a negligible density of the receptors that are being investigated. D2/3R density is typically 
ranked as follows (from high to low): putamen > caudate > thalamus > amygdala > hippocampus 
= temporal cortex > parietal cortex = occipital cortex = orbitofrontal cortex (Mukherjee et al., 
2002). Typical regions that are used as reference tissue are a white matter (WM) region, the 
superior longitudinal fasciculus (SLF), or traditionally, the cerebellum, as there are close to no 
DA receptors to be found in these regions. In this case, we used the SLF as a reference, which 
has been proven feasible for FAL PET (Ishibashi, Robertson, Mandelkern, Morgan, & London, 
2013). BPND estimations were calculated using the simplified reference tissue model (SRTM) 
according to (Ishibashi et al., 2013). The SRTM is based on a single-tissue compartment model 
(Ishibashi et al., 2013). SRTM can be used for FAL BPND. Time-radio-activity curves (TACs) on 
the basis of regions of interest (ROIs) were generated using predefined standard ROIs available 
through the Wake Forest University (WFU) PickAtlas (http://fmri.wfubmc.edu/ 
software/PickAtlas). The binding potential BPND was the primary PET outcome parameter.  
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III.3.4. Measurement and Assessment Protocol 
 
All participants signed a special informed consent form concerning PET/CT and were 
informed in detail about procedures, radiation exposure and related risks beforehand. Radiation 
exposure from each of the three low-dose CT scans was < 0.5 milli Sievert (mSv) effective dose 
(ED). The ED associated with the application of FAL was 4.3 mSv, resulting in an estimated 
total ED of 5.8 mSv associated with the study. 
Subjects were prepared with an i.v. catheter in one arm for the tracer application. 200 
megabecquerel (MBq) of FAL (MeanInjD = 196.87; SDInjD ± 9.89) was injected intravenously 
over 30 seconds. PET data was acquired in three bocks with a break between each of them (see 
figure 11):  
(1) 50 min emission scan, 30 min break;  
(2) 60 min scan, 60 min break;  
(3) 40 min scan.  
 
 
 
A low-dose CT was performed before each block for attenuation correction of the 
emission data. As participants were allowed to move during breaks, the separate low-dose CT for 
each block was necessary to avoid spatial mismatch between CT and PET caused by incomplete 
repositioning. Scanning took place until four hours after injection. Like this, FAL reached the 
wash-out phase even in high receptor density areas like the striatum.  
 
min 
Figure 11. PET/CT Assessment Protocol 
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III.3.5. Processing of PET Data 
 
After the acquisition of PET, the data of the first block was sorted into frames according 
to the following protocol: 3 x 20 s, 3 x 1 min, 3 x 2 min, 2 x 5 min, 3 x 10 min. PET data of the 
second and third blocks was sorted into frames of 10 min. The images were reconstructed by the 
3D iterative algorithm provided by the system software. Afterwards, the images of the 3 blocks 
were re-aligned using Statistical Parametric Mapping software package (SPM8, Wellcome 
Department of Imaging Neuroscience, Institute of Neurology, London; 
http://www.fil.ion.ucl.ac.uk/spm/). PET data were co-registered to each individual’s MRI scan. 
This method has been previously successfully applied in assessments using PET (Mukherjee et 
al., 2002) to combine higher-resolution anatomical information with functional information. 
 The distributions of grey matter (GM), WM and cerebro-spinal fluid (CSF) were 
calculated for every individual MR brain image and stereotactically normalized into a 3D MNI 
template space using SPM8. For group comparisons and explorative voxel-wise comparisons, we 
used SPM with the factor group (LR controls, HR controls, detoxified AUD patients). Further, as 
age showed to have different effects in patients compared to healthy participants (Rominger et 
al., 2012), we added age as a covariate as regressor of no interest. We used the Rex toolbox to 
extract all BPND values (measured by FAL) for several ROIs (see section III.3.5.1) based on our 
hypotheses. Data were transferred into SPSS to perform further statistical analyses (see section 
III.4.).  
 
III.3.5.1 Regions of Interest 
 
 The extrastriatal ROIs were generated using standard templates from Automated 
Anatomic Labelling (ALL) (Tzourio-Mazoyera et al., 2002), WFU PickAtlas 
(http://fmri.wfubmc.edu/-software/PickAtlas). Selection took place according to listed possibly 
affected regions and Brodmann areas (BA) in Goldstein & Volkow (2011) with the aid of the 
Online Brain Atlas Reconciliation Tool (http://qnl.bu.edu/obart). 
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The ROIs for the anterior cingulate cortex (ACC) were subdivided into rostral (rACC / 
BA 24), dorsal (dACC / BA 32) and subgenual ACC (sgACC / BA 25) in accordance with the 
suggested functional specialization (Bush, Luu, & Posner, 2000; Lumme, Aalto, Ilonen, Någren, 
& Hietala, 2007; Ko et al., 2009; Goldstein & Volkow, 2011). ROIs for the vlPFC were 
generated from corresponding templates from AAL including parts of BA 44 and 45 of the 
inferior frontal gyrus pars opercularis and triangularis. ROIs for the dlPFC were composed of 
templates for the superior and middle frontal gyrus including portions of BA 6, 8, 9, 10, 44 and 
45. ROIs for the mPFC were generated using the medial superior frontal gyrus template of the 
AAL atlas, including the GM belonging to the internal surface of the hemisphere anterior and 
superior to the cingulate gyrus. ROIs for OFC were composed of the orbital parts of the inferior, 
medial and superior gyrus partly including BA 10, 11 and 47. For an overview of all investigated 
ROIs and their anatomical localisation see table 6 and figures 12 to 16. 
Table 6. Investigated Regions of Interest 
dlPFC = dorsolateral prefrontal cortex; vlPFC = ventrolateral prefrontal 
cortex; mPFC = medial prefrontal cortex; OFC = orbitofrontal cortex; 
ACC = anterior cingulate cortex; sgACC = subgenual ACC; dACC = 
dorsal ACC; rACC = rostral ACC; R = right; L = left 
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Figure 12. ROI - Dorsolateral Prefrontal  
Cortex. (A) coronal view (B) sagittal view (C) 
axial view (D) 3 D view of the region of interest. 
Cyan = left, blue = right. 
Figure 13. ROI - Ventrolateral Prefrontal 
Cortex. (A) coronal view (B) sagittal view (C) 
axial view (D) 3 D view of the region of interest. 
Cyan = left, blue = right. 
Figure 14. ROI - Medial Prefrontal Cortex.  
(A) coronal view (B) sagittal view (C) axial view 
(D) 3 D view of the region of interest. Cyan = 
left, blue = right. 
Figure 15. ROI - Orbitofrontal Prefrontal 
Cortex. (A) coronal view (B) sagittal view (C) 
axial view (D) 3 D view of the region of interest. 
Cyan = left, blue = right. 
 53 
 
 
III.4. Statistical Analysis 
 
The statistical analyses were carried out using IBM SPSS Statistics Version 24.0 for Mac 
OS (IBM Corp., Armonk, NY) along with the description in Fields (2009). In a first step, we 
tested whether our data was normally distributed on the basis of Kolmogorov-Smirnov (K-S) 
tests and visually via Q-Q-plot results. We performed normality tests on the complete sample, as 
we consider AUD development as a continuous process. The K-S tests revealed non-normal 
distribution for a number of variables. The completion time for TMT-A (D(57) = 0.13, p < .05), 
TMT-B (D(57) = 0.15, p < .05), as well as scores for ADS (D(51) = 0.14, p < .05) and OCDS 
(D(53) = 0.14, p < .05) were significantly non-normal. Furthermore, BPND in the left vlPFC 
(D(58) = 0.13, p < .05) was significantly not normally distributed. As a number of variables were 
not normally distributed, we decided to use non-parametric tests (a series of Kruskal-Wallis (K-
W) tests) as an alternative to the one-way independent ANOVA (univariate analysis of variance). 
Differences between groups were confirmed by Mann-Whitney tests. Correlation of EF 
performance parameters, clinical scores and BPND in different ROIs were tested using 
Spearman’s correlation test. A two-sided p-value < .05 was set as the threshold for significance. 
Due to the explorative character of the study, we did not correct for multiple comparisons except 
in post hoc tests (Mann Whitney tests, Bonferroni correction) of significant results. The p-values 
of statistical tests are thus to be understood as exploratory ones with no confirmatory 
generalization of the results. 
Figure 16. Anterior Cingulate Cortex 
(A) coronal view (B) sagittal view (C) axial view 
of the regions of interest. Rostral ACC: blue = 
right, cyan =left; dorsal ACC: green = right, 
violet = left; subgenual ACC: yellow = right, 
red = left. 
 
 
All images of ROIs were produced using MRIcron 
(www.mricro.com) 
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IV. Results 
IV.1. Executive Function Test Performance 
 
Hypothesis 1.1 (H1.1): EF performance of HR controls and detoxified AUD patients is 
impaired when compared to LR control performance. 
Hypothesis 1.2 (H1.2): HR subject will lie on an intermediate performance level between 
LR and detoxified AUD. 
 
When looking into estimated IQ, TMT-A, semantic fluency and digit-symbol-coding 
performance using Kruskal-Wallis tests, no significant group differences were observed (see 
table 7). However, maximum digit span backwards remembered by the participants was 
significantly different between the groups (H(2) = 7.86, p < .05). Also TMT-B performance 
showed a trend to differ between groups (H(2) = 5.26, p = .073).  
Mann-Whitney tests were used to follow up these findings (see tables 8 and 9). A 
Bonferroni correction was applied for this step. As we compare LR with HR, LR with AUD as 
well as HR and AUD, all effects are reported at a .0167 level of significance (p < .05/3). It 
appeared that LR controls performed less strong on the digit span backwards test than HR 
controls (U = 87.50, z = -2.75, p = .006) and showed a trend to perform less strong than patients 
(U = 122.50, z = -1.93, p = .054). LR differed trendwise in terms of performance from AUD 
patients (U = 87.50, z = -2.75, p = .022); LR showed a decreased performance in TMT-B. Test 
performance compared between LR and HR in TMT-B and HR and AUD did not reach 
statistical significance. 
 
Table 7. Comparing Executive Function Test Performance amongst Groups 
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Figure 17. Digit Span Backwards Performance amongst Groups 
Significant Difference between Low Risk an High Risk Group (p < .0167); Difference between 
Low-Risk and Patients trending towards significance (p = .054) 
Table 8. Post Hoc Comparison between Low-Risk and High- 
Risk Controls 
Table 9. Post Hoc Comparison between Low-Risk Controls 
and Patients 
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IV.2. Extrastriatal Dopamine Receptor Availability 
 
Hypothesis 2.1 (H2.1): Extrastriatal D2/3R availability is lower in detoxified AUD than in 
LR and HR controls. 
Hypothesis 2.2 (H2.2): Extrastriatal D2/3R availability measured in HR subject will lie on 
an intermediate level between LR and detoxified AUD.  
 
As shown in table 10 and figure 19, extrastriatal BPND was significantly different in the 
rostral ACC of the right hemisphere (H(2) = 7.44, p < .05). The analysis also showed marginally 
significant results for group differences in the left rostral ACC (H(2) = 5.91, p = .05), the left 
dlPFC (H(2) = 5.54, p = .06) and left vlPFC (H(2) = 5.63, p = .06). Trends were observed on 
both hemispheres for the dorsal ACC (left: H(2) = 4.91, p = .09; right: H(2) = 5.22, p = .07) and 
for the right dlPFC (H(2) = 4.60, p = .10). BPND levels in the other ROIs did not differ 
significantly between LR, HR controls and AUD. For the post hoc tests, we decided to adapt the 
p-value to correct for multiple comparisons (p < .05/3 = p < .0167). The findings were followed 
up by Mann-Whitney tests (see table 11, 12, 13) showing significantly higher levels of 
Figure 18. Trail making Test Part A (TMT-A) and B (TMT-B) Performance amongst 
Groups                                                    Differences in TMT-B Performance trending towards 
significance for Low-Risk versus Patient Group     (p = .022; significance reported at p < .0167) 
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extrastriatal BPND in HR controls compared to AUD patients in the bilateral dorsal ACC (left: U 
= 103.00, z = -2.44 right: U = 101.00, z = -2.50; both p < .0167) and rostral ACC (left: U = 
94.00, z = -2.70 right: U = 83.00, z = -3.00; both p < .0167) as well as in the left dlPFC (U = 
99.00, z = -2.56, p < .0167) and left vlPFC (U = 96.00, z = -2.64, p < .0167). Differences 
between extrastriatal BPND in LR controls compared to AUD and LR to HR controls did not 
reach statistical significance, but showed trends to lie between the two latter (see figure 19, table 
12 and 13). 
 
Table 10. Comparing Groups and Regions of Interest 
Figure 19. Non-displaceable Binding Potentials (BPND) of 18F-Fallypride in selected 
Subregions of the Prefrontal Cortex (PFC)                 Significant Differences between High 
Risk and Patient group in bilateral dACC and rACC, left dlPFC, left vlPFC    (all reported at p < 
.0167). 
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Table 13. Post Hoc Comparison between Low-Risk and High-Risk 
Table 11. Post Hoc Comparison between High-Risk and Patients 
Table 12. Post Hoc Comparison between Low-Risk and Patients 
ACC = Anterior Cingulate Cortex; rACC= rostral ACC; dACC= dorsal ACC; PFC = Prefrontal Cortex; vlPFC = ventrolateral PFC; 
dlPFC = dorsolateral PFC; mPFC = medial PFC; OFC = Orbitofrontal Cortex; L = left; R = right 
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IV.3. Correlation of Executive Function Performance and Dopamine Receptor Availability 
 
 Hypothesis 3 (H3): Extrastriatal D2/3R availability is positively correlated to EF 
performance.  
 
Table 14. Correlations between Binding Potential and Test Scores I 
ACC = Anterior Cingulate Cortex; rACC= rostral ACC; dACC= dorsal ACC; sgACC = subgenual ACC; PFC = Prefrontal Cortex; vlPFC 
= ventrolateral PFC; dlPFC = dorsolateral PFC; mPFC = medial PFC; OFC = orbitofrontal Cortex; L = left; R = right; TMT-B = Trail 
making Test Part B; OCDS = Obsessive Compulsive Drinking Scale; ADS = Alcohol Dependence Scale 
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 Due to the dimensional understanding of AUD, we pooled the groups and performed the 
analysis on the complete sample. There was a significant positive relationship between the BPND 
in the left rACC and TMT-B completion time, rs = .29, p (two-tailed) < .05. The correlation 
between left dACC and TMT-B completion time also reached significance, rs = .30, p (two-
tailed) < .05 (see figure 20 and table 14). BPND is thus negatively correlated with EF 
performance in our observations. 
Figure 20. Scatterplots: Correlation of non-displaceable Binding Potential (BPND) for 
18F-Fallypride (FAL) in the left Anterior Cingulate Cortex (ACC) and Trail-Making-
Test (TMT-B) completion time. rs = Spearman’s rho 
rs = .29 
rs = .30 
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 When performing one tailed-tests, we observed additional significant results for the left 
dlPFC (rs = .25) and right dACC (rs = .25), (all p (one-tailed) < .05), see table 15 and figure 21. 
No correlation between D2/3 receptor binding and EF performance was observed in other cortical 
regions that are thought to be important for executive functioning.  
 Looking into clinical questionnaires, OCDS scores on the obsessive thoughts scale were 
significantly negatively correlated with BPND in the left rACC (rs = -.23), right rACC (rs = -.23), 
left dlPFC (rs = -.25) and left vlPFC (rs = -.24) (all p (one-tailed) < .05). Scores obtained in the 
ADS at baseline showed a significant negative relationship with BPND in the left rACC (rs = -
.26), right rACC (rs = -.26) as well as the left dACC (rs = -.24) (all p (one-tailed) < .05).  
Table 15. Correlations between Binding Potential and Test Scores II 
ACC = Anterior Cingulate Cortex; rACC= rostral ACC; dACC= dorsal ACC; sgACC = subgenual ACC; PFC = Prefrontal Cortex; vlPFC 
= ventrolateral PFC; dlPFC = dorsolateral PFC; mPFC = medial PFC; OFC = orbitofrontal Cortex; L = left; R = right; TMT-B = Trail 
making Test Part B; OCDS = Obsessive Compulsive Drinking Scale; ADS = Alcohol Dependence Scale 
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Figure 21. Scatterplots: Correlation of non-displaceable Binding Potential (BPND) for 
18F-Fallypride (FAL) and Trail-Making-Test (TMT–B) completion time ACC = Anterior 
Cingulate Cortex; PFC = Prefrontal Cortex; rs = Spearman’s rho 
 
rs = .25 
rs = .25 
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For visual purposes, we also show the whole brain activation pattern amongst all 
participants measured with FAL PET with its effects of interest (EOI) in figure 22 below 
(threshold p < .01). 
 
Figure 22. Fallypride PET map - Whole Brain Activation throughout 
all Groups measured with 18F-Fallypride PET. (A) coronal view (B) 
sagittal view (C) axial view; (1) Activation in the Anterior Cingulate 
Cortex; (2) striatal and mid-brain activation. Results are thresholded 
with p < .01. 
A B 
C 
R L 
2 
1 
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V. Discussion 
V.1. Summary 
 
The present study investigated the relationship of extrastriatal D2/3R availability and EF 
performance in alcoholic patients and control groups. Of special interest was the focus on the 
dimensional approach of AUD for which we included an HR control group of subjects with 
problematic alcohol consuming patterns as defined above (chapter II.1.1.2.). The inclusion of 
regularly consuming participants adds another level to the investigation, as this has not been a 
main focus in alcohol research so far. EF performance amongst the groups differed in two tasks, 
TMT-B and digit-span backwards, with the latter showing a significantly better performance of 
AUD compared to LR. Surprisingly, TMT-B performance showed a trend to be less strong 
amongst controls when compared to HR and AUD. Neuroimaging investigations showed a 
difference in extrastriatal D2/3R availability in several ROIs (bilateral dACC, bilateral rACC, left 
dlPFC and left vlPFC). The main difference was observed between HR and AUD, with patients 
showing significantly less BPND than HR in a number of these areas (bilateral rACC, bilateral 
dACC, left dlPFC and left vlPFC). Extrastriatal D2/3R availability in the left rACC, bilateral 
dACC and left dlPFC was positively correlated with TMT-B completion time and thus 
negatively correlated with EF performance measured by this test. Clinical scores such as OCDS 
obsessive thoughts and ADS showed a negative correlation with extrastriatal D2/3R availability.  
 
V.2. Executive Function Test Performance 
 
In contrast to our hypotheses (H1.1 and H1.2) and to previous reports (Goldstein & 
Volkow, 2011; Houston et al., 2014; Ratti et al., 2002; Zinn et al., 2004) AUD patients and HR 
controls performed better on EF tests than LR controls in the present study. This is a new aspect 
and leading us to reject H1.1 and H1.2 for this sample. To some extent, these observations may 
be related to the following possible explanations.  
First, when investigating EF and stating impaired EF, findings could always be due to 
other influencing factors such as stress, lack of sleep, loneliness, lack of physical exercise or 
motivation, etc. All of these factors can influence the examined person’s ability to display the EF 
of which he/she is actually capable (Diamond, 2013). Observed impairments and lesions may 
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thus decrease and increase throughout consumption, withdrawal, lasting sobriety and relapse in 
the sense of dynamic lesions. Another challenge in the assessment of EF is the high sensitivity to 
any kind of disruption and the relatively low specificity of the tests. Second, EF is not a strict 
construct or trait and can be influenced and improved by training. Hence, subjects who have 
performed similar or even the same tests previously in their lives have an advantage compared to 
those who have never performed any of these tasks. In our case, it is possible that especially 
participants from the AUD group have already taken similar tests. They have spent time in 
clinics and therapeutic settings, where the evaluation of abilities with the help of standardized 
tests as those used in the present study are frequently administered. Third, it is possible that due 
to the complex study design with its demanding assessment sessions, we provoked a selection 
bias. Possibly only highly functional AUD patients with rather intact EF patterns were able to 
complete all of the assessments and were thus included in the final sample. Patients with 
impaired EF might have not been able to manage planning ahead and committing to multiple 
appointments over a number of days leading to exclusion from the final sample. Fourth, 
impairment of EF is not referable solely to alcohol consumption – their development can be 
disrupted in adolescence or be influenced by other factors such as age, gender, IQ and education 
years or other diseases and disorders (for an overview of differential diagnoses of impaired EF, 
see Rabinovici et al. (2015)). The influence of these factors was limited by defining explicit 
exclusion and inclusion criteria, aiming for the least possible differences when comparing groups 
in core descriptive factors (see table 5, chapter III.1.3.). However, it is possible that other factors 
than alcohol consumption presented by our participants explain the differences observed in EF 
performance. Last, on a suggestive level of interpretation, it is also probable that the weaker 
performance of LR controls may be due to a lack of motivation to show their intact functionality. 
Healthy controls might not show as much interest in the study content and findings, as they are 
not as personally involved as affected individuals (namely the AUD group). This could have a 
non-negligible impact on each participant’s motivation and the individual test performance 
which is highly linked to motivation. AUD patients who have gone through detoxification in 
specialised wards and who are aware of their disorder, are possibly eager to find out more about 
AUD and might even see this as an opportunity to prove their functionality (despite their 
diagnosis) in this kind of setting.  
This study underlines the diversity of EF performance amongst participants and shows 
that high functionality amongst AUD patients is not excluded. In general, it might be possible 
that patients profit from detoxification treatments in terms of an amelioration of EF performance, 
which, however, we cannot verify with this study. If one interprets these results on a very 
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speculative level, it might be conceivable that our sample of AUD consists of individuals that 
possibly had a higher IQ before suffering from an AUD and lost some of these cognitive 
capacities due to chronic alcohol consumption. Possibly they have residual EF capacities at their 
disposal that were neither affected by the consumption nor reflected in the IQ and that allow 
them to do better on the EF tests than the control groups.  
However, the conclusion of our results according to Bates (2000) suggests that this 
particular patient sample has a higher probability to successfully complete treatment, to stay 
abstinent for a longer time period and to have better social and professional outcomes. This 
could be assumed for our sample, as a number of the participants were already measured quite 
late after their last drink (MeandaystoPET = 36.4; SDdaystoPET = 20; min = 9, max = 96 days), 
indicating a certain level of resilience and commitment, as they were able to remain reliably 
abstinent for the assessments and testing sessions. For a verification of this hypothesis, an 
analysis of our follow-up data might give more insight. 
 
V.3. Extrastriatal Dopamine Receptor Availability 
 
The effects of alcohol consumption on extrastriatal DA transmission have not been in the 
focus of AUD research until recently. This is also reflected by the limited number of references 
when searched for on PubMed (e.g. 12 results for studies with humans when searching for 
((extrastriatal) AND dopamine) AND alcohol in a search performed on November, 6th, 2017). 
This study is adding a rather large body of work, as FAL PET was performed on a relatively 
large sample (N = 58) to evaluate influences of alcohol on extrastriatal DA. 
An especially interesting finding of the present study is the pronounced difference in 
extrastriatal D2/3R availability between HR and AUD participants despite the absence of 
significant differences when comparing LR to AUD or to HR. This is partly in line with previous 
research that failed to find differences in baseline receptor availability between healthy controls 
and abstinent patients (Narendran et al., 2014). As proposed in H2.1, we observed lower 
extrastriatal D2/3R availability in AUD compared to a control group. This possibly reflects a 
reactive down-regulation of DA receptors due to high dopaminergic stimulation during long 
lasting and excessive consumption patterns. Multiple studies were able to show similar effects 
mainly in striatal regions in recently abstinent alcoholics (Heinz et al., 2004; Thiruchselvam, 
Malik, & Foll, 2017; Volkow et al., 2002). Yet, in this study this observation was made when 
comparing AUD with HR controls and not with LR controls.  
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As we suggested in H2.2, beginning neuroadaptations in terms of a loss in DA receptor 
availability during chronic alcohol abuse (represented by our HR group) was not confirmed by 
our findings and led to the rejection of the hypothesis. Our results rather indicate the opposite: 
we saw an elevated level of free receptors in extrastriatal regions in participants with problematic 
alcohol intake when comparing with AUD and LR. A possible explanation for this condition 
may be linked to a crucial and fundamental difference between HR participants and the other 
groups: HR controls were maintaining an active drinking status in the days and weeks previous 
to our examinations, whereas AUD were obliged to be abstinent and LR did not drink alcohol or 
just very small amounts. As mentioned above, the results showed an additional trend towards 
higher levels of free DA receptors in HR than in healthy controls. This relationship was, 
however, not statistically significant and the mechanisms that lead to these observations are not 
easily determined.  
Nevertheless, there have been studies that observed similar results for chronic alcohol 
abuse. Leggio et al. (2014) showed the crucial role of D3R in mice for the reinforcing 
mechanisms of alcohol intake. These mechanisms are probably pronounced stronger in HR 
controls than in LR subjects and account at least partly for their alcohol related behaviour. 
Furthermore, recent findings seem to suggest upregulation of D3R in extrastriatal areas (e.g. 
hypothalamus, substantia nigra, ventral pallidum) across different SUDs (Thiruchselvam et al., 
2017) which would be consistent with our findings in HR subjects. This would, however, not be 
in line with our findings in AUD. Thus, our investigations leave the following question 
unanswered: at what point does the decrease in receptor availability occur or start if we consider 
AUD as a dimensional construct?  
 
From another point of view, one could suggest that higher levels of extrastriatal D2/3R 
availability might be a preliminary trait and that high levels could be a protective factor to 
prevent HR controls from actually developing a manifest AUD condition. It might be one of the 
compensational mechanisms that HR have to prevent their risky consumption pattern from 
further development towards AUD. The protective characteristic of higher D2/3R availability has 
been proposed amongst others by Volkow et al. (2006) for non-affected members of alcoholic 
families. On the contrary, LR controls showed levels of D2/3R availability to be between those of 
HR and AUD which does not support this theory (it is worth noting that the differences between 
HR and LR and AUD and LR were not statistically significant). Hence, other protective 
mechanisms and compensations such as genetic, epigenetic and social and behavioural factors 
are very likely to play a role in individual resilience towards AUD (see chapter II.1.3. on 
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aetiology and risk factors). Higher levels of D2/3R availability amongst HR also implicate the 
same questions as the more frequently discussed and observed lower levels of D2/3R availability 
in AUD: is this state a pre-existing or an acquired condition? Currently, we cannot fully answer 
this question. 
 
Focussing on the affected regions in the brain, our study revealed changes in important 
extrastriatal regions: the ACC, the dlPFC and vlPFC. Alterations in these regions seem coherent 
when looking into AUD research. Further, many of the deficits in behaviour and learning 
associated with addictions can be connected to these regions.  
The ACC has traditionally been seen as part of the limbic system of the human brain and 
it receives projections of the mesocorticolimbic pathway. It is thought to be highly involved in 
higher cognitive and emotional processing (Bush et al., 2000). Distinct roles are associated with 
the ACC, such as the involvement in maintaining divided attention, the development of novel 
responses, and the adaption of on-going behaviour through conflict monitoring and evaluation of 
errors (Carter & van Veen, 2007; MacDonald, Cohen, Stenger, & Carter, 2000). The latter seems 
to be engaged by negative feedback or conflicting responses. The conflict-control-loop theory 
(Carter & van Veen, 2007) promotes ACC activation through errors and negative feedback, 
causing dlPFC activation and reinforced attention, influencing the behavioural outcomes and 
actions. This emphasises the connectivity of ACC and dlPFC. Furthermore, the distinction of the 
ACC into a cognitive part (the dACC) and an emotional / affective ventral part (the rACC) has 
been widely accepted (Bush et al., 2000). Various functions have been ascribed to the 
subdivisions: the dACC seems to be involved, amongst others, in the modulation of attention and 
EF by sensory and response selection, error detection, motivation and working memory. Along 
with its functions, the ACC’s high interconnectivity with the lateral PFC, the parietal and motor 
and supplementary motor cortex should be pointed out (Bush et al., 2000). The emotional / 
affective subdivision shows strong connections to other parts of the brain such as the OFC, 
insular cortex, NAC, amygdala and hippocampus. This part is believed to be involved in the 
assessment of salience of emotional and motivational information as well as in emotion 
regulation (Bush et al., 2000). As described by Goldstein & Volkow (2011), the dorsal PFC 
(including dACC and dlPFC) is thought to be predominantly involved in top-down control and 
the vlPFC in automatic response tendencies (for example, drug-related attention bias) and 
impulsivity. An altered DA modulation in these regions due to the consumption of addictive 
drugs (such as alcohol) seems plausible. 
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It is thus not surprising to find alterations between HR and AUD present in both the 
rostral and the dorsal parts of the bilateral ACC as well as in the left dlPFC and vlPFC.  
 
Finally, also technical factors and uncertainties need to be included in this discussion. As 
FAL binds D2R and D3R, it is difficult to distinguish between these two receptor subtypes and 
state if an increased/decreased BPND is due to increased/decreased D2R or D3R availability or 
both. A number of studies have tried to map receptor distributions, to determine and distinguish 
the role of D2R and D3R. Results showed rather low concentrations of D3R in the cortical areas 
(Hall et al., 1996). Furthermore, it is not entirely clear if an increase in BPND reflects a higher 
absolute number of DA receptors or rather relatively more available/free receptors due to lower 
DA concentrations. Or inversely, if lower levels of BPND reflect a lower total number of DA 
receptors or solely less free receptors due to higher DA concentrations (Hirth et al., 2017). 
Moreover, modulation of transmission at receptor level such as phosphorylation of the receptor 
itself or its associated G-proteins, altered pathways or internalisation of the receptor are possible 
but cannot be distinguished in the analysis. Altogether, BPND reflects the individual relationship 
between free DA receptors and DA concentrations relative to a reference region with a negligible 
concentration of DA receptors. This needs to be considered when interpreting results. To clarify 
the relation between DA concentrations and free receptor concentrations, the observation of 
tracer displacement, alterations in BPND during task performance (e.g. response inhibition tasks 
as shown in Albrecht, Kareken, Christian, Dzemidzic, & Yoder, 2014) or direct measures of DA 
release (e.g. with a combination of different measures as indicated in figure 4) might be helpful 
for future investigations.  
Possible explanations for the lack of observed differences between LR controls and the 
two other groups may thus be also linked to methodological and technical procedures (see 
limitations in section V.5.). Furthermore, it is conceivable that our a priori chosen and generated 
ROIs were not the right ones to detect the suspected alterations. However, on the basis of 
previous research we carefully chose and defined ROIs that are thought to be affected in alcohol 
consumption as well as in EF disruption.  
Still, it can be said that alcohol consumption has an impact on extrastriatal D2/3R 
availability and influences DA transmission, especially in subregions of the ACC, dlPFC and 
vlPFC.  
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V.4. Correlation of Executive Function Performance and Dopamine Receptor Availability 
 
It has been widely reported that DA has an important role on the modulation of PFC 
activities (Robbins & Arnsten, 2009) to which EF are usually attributed. Our results suggest that 
certain aspects of EF such as working memory, set shifting and mental flexibility, indexed by the 
TMT-B, may be related to extrastriatal D2/3R availability in individuals who abuse alcohol. Yet, 
EF performance was negatively correlated with receptor availability. These data were contrary to 
our hypothesis (H3) and led to its rejection. However, other authors have also made similar 
observations. In a recent study Vyas et al. (2017) described an association of better EF 
performance (WCST) with low extrastriatal BPND in schizophrenic patients which correspond to 
our investigation into AUD. The authors, however, showed that in healthy volunteers EF 
performance was positively correlated with BPND (thus with higher DA receptor availability and 
supposedly less DA function). They suggest that this relationship might represent an adaptation 
of disturbed DA circuitry connections. A similar interpretation may be possible for AUD in our 
study. Another study by Lumme et al. (2007) showed a positive correlation between the BP of 
[11C]-FLB 457 in the right ACC and non-perseverative errors in the WCST. These data are in 
line with our findings that indicate a positive correlation of FAL BPND in the left ACC, right 
dACC and left dlPFC with TMT-B completion time throughout all groups. Nevertheless, Lumme 
et al. investigated 32 healthy, non-smoking controls with no history of psychiatric disorders.  
As illustrated by our observations and other studies, lower extrastriatal D2/3R availability 
could predict better performance in EF tasks. The exact role of D2/3R availability in EF is, 
however, not clearly delimited as animal studies showed no relevant impairment of cognitive 
functions during a D2R bloc situation (Floresco et al., 2006; Granon et al., 2000).  
Taken together, the complex and apparently heterogeneous involvement of DA in the 
modulation of PFC functioning and extrastriatal regions in AUD is very likely but not finally 
clarified. 
It is worth noting that a positive correlation of BPND and EF performance has also been 
previously described for striatal regions (Ballard et al., 2015; Chen et al., 2005; Christopher et 
al., 2014). An investigation of this association would have exceeded the scope of this work but 
would present an interesting focus for future investigations, as the named studies did not 
investigate AUD patients. Negative correlations of extrastriatal D2/3R availability with OCDS 
thoughts and ADS scores are in line with observations made in nicotine-dependent subjects 
(Fehr et al., 2008), especially in regard to the ACC.  
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V.5. Limitations of this Work 
 
 Before giving perspectives on the basis of this work, a few limitations to this study have 
to be discussed. First, when investigating EF, we are confronted with an overall, general 
challenge. The high variability of EF constructs and of operational design of EF tests, make it 
hard to compare and interpret findings from different studies (Day et al., 2015). Second, the 
great variance concerning the moment of PET assessment (between 9 and 96 days after drinking 
the last alcoholic beverage) in AUD might have an influence on receptor availability: it is 
thought that availability normalises with long-term abstinence (Rominger et al., 2012). Long 
time spans between first assessments and PET were inevitable to a certain extent as problems 
with tracer synthesis and limited time slots to use the PET scan were not predictable. Hence, it 
would have been of interest to analyse the time of abstinence (between last drink and PET 
measurement) in controls as well as in AUD to increase the comparability and interpretability of 
the findings. The inclusion of the duration of abstinence as a covariate seems inevitable for 
future studies, especially if we assume that AUD patients can recover from hypodopaminergic 
states. Still, this great range was partly due to one outlier with 96 days and three more with more 
than 50 days between the cognitive assessment and PET. Moreover, other studies did present a 
similar range of days between their first day of abstinence and the PET assessment (Heinz et al., 
2009). Third, observed relationships between neuroimaging results and test performance are 
based on correlations that exclude conclusions concerning their causality. Moreover, our 
conclusions are limited, as the correlation coefficient rs (Spearman’s rho) was rather small (from 
.289 to .297 for two-tailed tests and between .251 and .297 for one-tailed tests) within our 
significant results. Therefore, a cautious interpretation of the results is inevitable. Fourth, the 
present group of AUD patients seems to represent a rather high-functioning group in terms of 
EF. Due to the rather complex design of this study, the selection of probably highly functional 
AUD was inevitable in some ways. However, lower functioning AUD patients would be 
predicted to show stronger differences in EF-associated measures. Fifth, another limitation is the 
separation of neuropsychological assessment and the evaluation of BPND in the scanning session. 
Accordingly, correlations between D2/3R availability and EF performance can only reflect trait 
features. In addition, the spatial resolution of the detectors and the kinetic energy of the e+ limit 
the total resolution of PET to 1-2 mm in humans (Mikla & Mikla, 2014). This has and influence 
on registered emission and especially on the allocation of detected emission to a specific site in 
the human brain. Especially in smaller ROIs, like the subdivisions of the ACC, this mechanism 
could have an impact on results. Nonetheless, BPND values determined with WM as the reference 
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region (the SLF in our study) are normally higher than BPND values determined with the 
cerebellum as a reference (Ishibashi et al., 2013). Also, there is a controversy that FAL might not 
be the optimal substance to investigate cortical regions, as high variability in BPND and low 
baseline values are often observed (Slifstein et al., 2010). For our investigation the use of FAL 
was highly suitable and justified, as we were interested in investigating striatal (Spitta, 2018) and 
extrastriatal D2/3R availability.  
 And lastly, the inclusion of a number of women in each group (LR = 3, HR = 2, AUD = 
3) can be criticized. We did not differentiate between sexes when evaluating drinking habits and 
assigning participants to HR and LR groups. The percentage of women in each group is, 
however, relatively low and not significantly different between the groups. This is why we 
decided to apply the same criteria to men and women in the context of this study. The inclusion 
of sex differences, nicotine dependence, other individual characteristics and pre-morbid 
vulnerabilities (e.g. genetic predispositions) might be crucial for interpreting the observed results 
more accurately. 
 
V.6. Conclusion and Perspectives 
 
AUD is a complex, relapsing disorder that is often associated with deficits in higher 
cognitive control mechanisms and alterations of the dopaminergic neurotransmitter system. This 
study is adding more evidence to a growing body of work with very heterogeneous results 
concerning dopaminergic responses to chronic alcohol consumption and its impact on EF 
performance. The findings may contribute to a deeper understanding of the multiple 
pathomechanisms involved in AUD. The differences observed in D2/3R availability between the 
groups show that besides the striatal differences which are more often investigated, further 
alcohol consumption-induced changes in frontal areas are likely. Such changes might be of great 
interest for the general understanding of AUD, other addictions and related diseases, but also for 
the development of new treatments and interventions. However, clearly more research is needed, 
also in terms of prediction of the course of the disease, as a majority of patients (up to 80%) with 
AUD suffer a relapse.  
 
For future research, it might be interesting to investigate in the direction of, and with 
respect to, some of the following aspects. It would be of great interest to use standardized ROIs 
for investigating extrastriatal regions. Up to now, this is possible to a limited extend as the ALL 
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and WFU PickAtlas provide a number of ROIs, but there is no official consensus on regions 
such as the so called dlPFC or the vlPFC. A standardized nomenclature of ROIs across studies 
would facilitate the comparability of different studies and would make it easier to reproduce, 
verify and interpret findings. As already stated by other authors, especially longitudinal and 
interventional studies are needed to clarify if the differences in the dopaminergic system 
observed in SUD either precede or result from chronic use and abuse and where alterations 
principally take place (DA release vs. receptor concentrations). Furthermore, especially the 
relationship between prefrontal glutamate and extrastriatal D2/3R availability could present a 
future focus as the DA system is believed to be potentially regulated by glutamatergic 
transmission (Gleich et al., 2015). It would also be of great interest to investigate striatal 
alterations in D2/3R availability throughout the groups, that we observed in our sample (Spitta, 
2018) in combination with EF performance. Finally, the future perspectives of EF as a target of 
therapy in the treatment of AUD need to be investigated and evaluated. Presumably, DA 
modulation on extrastriatal regions such as the PFC could have an impact on the success of 
treatment outcomes and relapse.  
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